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Abstract 
 
Background: Incorporating patient preferences in treatment planning has become 
increasingly important. Despite the growing literature on preferences for the treatment of 
psychosis, there have been no systematic reviews on the ways that such preferences have 
been elicited. 
Objectives: This review examined methods used to elicit treatment preferences for psychosis 
and to evaluate the strengths and the weaknesses of each method. 
Method: PsycINFO, Psychology and Behavioural Sciences Collection, MEDLINE, 
EMBASE and CINAHL were searched for relevant articles. The electronic database of a key 
journal, ‘Schizophrenia Research’, was also searched. Finally, the methodological quality of 
included studies was assessed. 
Results: There were variations across studies concerning the types of treatments subjected to 
preference assessment, the types of problems examined, and the methods used. A lack of 
information regarding preference elicitation made methodological comparisons difficult and 
limited the ability to derive any robust conclusions about the utility of each method. The use 
of non-standardised elicitation methods was common across studies.  
Conclusion: Researchers should apply rigorous methods, which involve the provision of 
information to patients, to obtain valid preferences. Further research is required to build on 
the findings of this review and include other methods that may be of use. 
 
Keywords: Psychosis, treatment preference, preference elicitation. 
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1. Introduction 
 Taking account of patient preferences in treatment planning is essential in providing 
patient-centred care (Green et al., 2014), and has been associated with improved outcomes, 
increased patient satisfaction and treatment adherence (Lindhiem, Bennett, Trentacosta, & 
McLear, 2014). Clinical practice guidelines & UK policy directives have also argued that 
patient involvement in their treatment is an indicator of high-quality mental health care and 
should be facilitated (Department of Health, 2012; National Institute for Health and Clinical 
Excellence, 2009).  However, there is little evidence that patient preferences relating to their 
treatment are accommodated (Goss et al., 2008) as there are often significant differences in 
the priorities of patients and clinicians (Greenwood et al., 2010). 
 
1.1. Operationalisation of Treatment Preferences 
 
Despite its wide use, the term ‘treatment preferences’ lacks a clear and consistent 
definition. Most studies in the area of mental health have used the term to describe the 
‘relative desirability of a range of treatment options’ (Brennan & Strombom, 1998), 
treatment goals or outcomes (Byrne, Davies & Morrison, 2010). Other studies have attempted 
to elicit preferences by exploring patients’ attitudes, satisfaction or experience with a 
treatment intervention (Klose et al., 2016). Klose et al. (2016) have proposed a new 
conceptual framework for patient preference in healthcare, in which preference is viewed as a 
choice over a treatment option. This choice involves an understanding of the treatment option 
presented (Corrigan & Salzer, 2003), as well as a perception of how beneficial this treatment 
is (Becker, Darius, & Schaumberg, 2007). Thus, they propose that preferences regarding 
treatment outcomes differ, as they focus on patients’ preference over a health status (e.g. 
improved social functioning), whereas preferences over health experiences focus on 
treatment elements the person has found helpful.  
4 
 
1.2. Rationale for this review 
 
Despite the importance of patient preference on treatment outcomes and adherence, 
only a few systematic reviews looked at the preferences for psychosis treatment (McHugh, 
Whitton, Peckham, Welge, & Otto, 2013; Eiring et al., 2015) and the effects of these on 
treatment outcomes and satisfaction (Lindhiem et al., 2014). Of these, Eiring et al. (2015) 
examined whether patients prefer pharmacological over psychological treatments, whilst 
McHugh et al. (2013) explored preferences for pharmacological associated treatment 
outcomes. To our knowledge, there have been no efforts to systematically review and 
synthesize information about the ways that preferences for the treatment of psychosis are 
assessed.  
1.3. Systematic Review Questions  
 
This review will answer the following questions: 
 What are the various methods of assessing treatment preferences in research with 
people diagnosed with psychosis? 
 What are the strengths and weakness of each method? 
 
2. Materials & Methods 
A review protocol was developed and registered on PROSPERO (registration number 
CRD42019129702;  accessible at: 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019129702).  
 
2.1. Search Strategy 
 Searches of the Cochrane database and PROSPERO were completed prior to 
conducting the review to ensure there were no existing reviews on the selected subject.  
PsycINFO, Psychology and Behavioural Sciences Collection, MEDLINE, EMBASE and 
CINAHL were searched in March 2019 for relevant articles. The electronic database of a key 
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journal (‘Schizophrenia Research’) was also searched to identify any studies missed by the 
electronic searches. Search terms were developed after searching the PubReMiner database 
and looking at previous systematic reviews on treatment preferences (Appendix 1.2). A 
subject librarian was also consulted due to the differences in the indexing of search terms 
across databases. The final search algorithm for title, keyword and abstract searches was:  
1. Psychosis OR Psychoses OR Psychotic* OR schizo* 
AND 
2. (Treat* or Patient* or Client*) ADJ2 (Prefer* or Priorit*) 
AND 
3. Measur* OR assess* OR evaluat* OR explor* OR identif* OR investigat* OR elicit* 
OR scale* OR tool* OR survey* OR interview* OR questionnaire* OR focus group 
 
2.2. Eligibility Criteria 
Studies meeting the following criteria were included in review:  studies with adults 
diagnosed with schizophrenia or schizophrenia spectrum disorder; studies published in 
English language; in peer reviewed journals; between the years 2000 to 2019; full text 
availability; and studies exploring self-reported stated preferences. No restrictions were 
applied to study design or methodology. Furthermore, the scope of this review was restricted 
to preferences for treatment options (Klose et al., 2006). Thus, studies of patient satisfaction, 
attitudes or experience were excluded. Similarly, studies on patient’s quality of life, preferred 
outcomes, or studies exploring preferred elements or attributes of care in general that were 
not specific to psychosis were excluded. Studies on pathways to care and help seeking 
behaviour were also excluded as they involved review of observed data or non-clinical 
populations. Moreover, among Randomised Controlled Trials (RCTs) the assessment of 
preference must have occurred prior to the selection of (or randomization to) treatment. 
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Finally, studies involving individuals with various diagnoses, where those with psychosis 
consisted of less than 50% of the total sample were excluded.  
 
2.3. Quality Appraisal Strategy 
The methodological rigour of the studies was assessed using Version 1.4 of the Crowe 
Critical Appraisal Tool [CCAT] (Crowe & Sheppard, 2011; Crowe, 2013).  The CCAT 
consists of 22 items, across eight categories (Appendix 1.3). Each category has multiple item 
descriptors, which are rated on a nominal scale as Present, Absent or Not Applicable. Each 
category is then rated on a 6-point scale from 0-5, with lower ratings reflecting lower quality. 
Following scoring of each category, a total score and a total percentage were given to each 
study. Walsh and Downe’s (2006) qualitative descriptors were used to interpret the results of 
the appraisal. Thus, studies demonstrated ‘good’ quality if they received a total percentage of 
>75%, showed ‘acceptable’ quality if they scored >50%, and were of ‘poor’ quality if they 
scored <50%. 
To improve the rigour of the methodological critique, an independent reviewer also 
assessed five of the included studies for risk of bias. There was an 87.5% agreement between 
the author and the independent rater and discrepancies were resolved through discussion.  
 
2.4. Data Extraction & Synthesis 
All data were extracted using a standardised data extraction form which was adapted 
from Eiring et al. (2015) to match the purpose of this review (Appendix 1.4).  Due to the 
nature of this review (exploratory, mixed-methods review) and the heterogeneity of the study 
methodologies and designs, a narrative synthesis approach was undertaken to synthesise the 
data (Siddaway, Wood & Hedges, 2019). 
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3.  Results 
3.1. Study Selection 
The search yielded a total of 2723 results, of which 757 duplicates were removed 
using EndNote X9.  The author screened the titles and abstracts of 1966 articles for relevance 
and following this, the full-texts of 25 articles. Of these, the full-text of one article was 
retrieved via university inter-library loans and, following screening, it was excluded, as it did 
not report sample characteristics. The rest of the articles were excluded for reasons shown in 
Fig. 1. This resulted in 12 studies being included in the review. 
  
Fig 1. PRISMA flow diagram  
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3.2. Study Characteristics 
The 12 studies included in the review spanned the years 2003-2018 and were 
conducted in the United Kingdom (6) United States of America (2), Germany (2), France (1) 
and Taiwan (1).  
3.2.1. Study Design  
All studies employed a cross-sectional design except Wilder, Elbogen, Moser, 
Swanson & Swartz (2010), who compared medication preferences to prescribed medications 
over 12 months as part of a larger RCT. One study, which was also a sub-study of an RCT, 
used thematic analysis to examine crisis plans, a form of advance statements (Farrelly et al., 
2014).  Two studies employed a sequential mixed-methods design to first elicit patient 
preferences and then explore the reasons of such preferences (Caroli et al., 2011; Sumner et 
al., 2014). Four were survey or questionnaire studies (Crawford, Gibbon, Ellis, & Waters, 
2004; Huang, Shang, Shieh, Lin & Su, 2011; Moritz, Berna, Jaeger, Westermann, & Nagel, 
2017; Patel, De Zoysa, Bernadt, & David, 2009) and used a single group design, except Khan 
and Pillay (2003), who conducted a comparative study. One study used a Patient Preference 
Trial (PPT) design (Haddock et al., 2018), one a Discrete Choice Experiment (DCE) design 
(Levitan et al., 2015), while Mendel et al. (2011) used an experimental, randomised, 
between-groups design.  
3.2.2. Participant characteristics.  
The number of participants in each study ranged from 55 to 271. Mean age was 39.38 
years (reported in 10/12 papers). 56.95% of participants across the studies were male (range: 
37.5- 75.6%), and all but two studies (Huang et al., 2011; Mendel et al., 2011) recruited 
outpatients. 62% of participants across the studies were White/Caucasian (based on 8/12 
studies reporting ethnicity distribution). All studies recruited individuals with affective and/or 
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non-affective psychosis, whereas two studies also recruited participants with multiple 
sclerosis (Mendel et al., 2011), substance misuse, neurosis and personality disorder diagnoses 
(Crawford et al., 2004).  
3.3. Aspects of Preference Elicitation   
 3.3.1. Methods of Preference Elicitation  
All studies used self-report methods, with six studies using surveys or questionnaires 
with closed questions to elicit preferences (Caroli et al., 2011; Crawford et al., 2014; Khan & 
Pillay, 2003; Moritz et al., 2017; Patel et al., 2009; Sumner et al., 2014). In these studies, 
participants were presented with various treatment options and were asked to choose the one 
they preferred the most. Their responses were either discrete (e.g. prefer A vs prefer B) or 
graded (e.g. strongly prefer A vs prefer A vs indifferent etc.). Open-ended questions were 
also included in three of these studies (Caroli et al., 2011; Khan & Pillay, 2003; Sumner et 
al., 2014) and in Haddock’s et al. (2018) study to explore the reasons for participant choices. 
In Haddock’s et al. (2018) study a semi-structured interview which included closed, open-
ended questions and a preference scale were used, whereas Mendel et al. (2011) used a 
hypothetical scenario to elicit preferences.  Finally, Huang et al. (2011) designed a brief scale 
to assess treatment seeking behaviour and preferences (‘The Preference for Treatment 
Scale’).  This was a Likert Scale measuring relative preference between psychiatric and 
religious intervention. There was no information provided on the psychometric properties of 
this scale.  
Most questionnaires were completed in face to face meetings with the researchers, 
apart from one study which posted a survey on the internet (Moritz et al., 2017).  Levitan et 
al. (2015) also recruited participants though an online patient panel. In their study, 
participants completed an online survey and preferences were elicited via a series of choice 
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tasks drawn from DCE methodology, where participants were asked to indicate which of 
several hypothetical treatment alternatives they think is better for a hypothetical patient with 
schizophrenia.   
Finally, two studies assessed treatment preferences though the review of advance 
statements, such as Joint Crisis Care Plans (JCPs) and Psychiatric Advance Directives 
(PADs) (Farrelly et al., 2014; Wilder et al., 2010). These were studies that explored treatment 
preferences in the event of a future relapse or mental health crisis. JCPs were completed 
jointly in a meeting with the patient, their clinician and an external facilitator. PADs were 
also completed during a structured interview with a facilitator. 
 3.3.2. Categories presented for preference elicitation  
Four studies asked patients to choose from different types of antipsychotic medication 
or drug formulations, such as oral or injectable medication (Caroli et al., 2011; Levitan et al., 
2015; Patel et al., 2009; Wilder et al., 2010). Two studies explored preference regarding the 
delivery, setting or intensity of treatment patients wished to receive (e.g. treated at home vs 
hospitalisation) (Crawford et al., 2004; Khan & Pillay, 2003).  Two studies (Haddock et al., 
2018; Sumner et al., 2014) offered choices between different modalities of psychological 
interventions and treatment as usual, compared to Huang et al. (2011) and Moritz et al. 
(2017), who asked participants to choose from a variety of interventions, including medical 
and non-medical treatments. Finally, two studies did not explicitly state the options presented 
(Farrelly et al., 2014; Wilder et al., 2010).  
 3.3.3. Psychoeducation about treatment options 
Five out of 12 studies provided explanatory information regarding the treatment 
options presented to participants (Crawford et al., 2004; Haddock et al., 2018; Farrelly et al., 
2014; Mendel et al., 2011; Sumner et al., 2014). All four of these reported providing brief 
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information sheets or verbal information, compared to Crawford et al. (2004) who only 
provided clarification of the term ‘compulsory treatment’. 
 3.3.4. Sources used in option selection.  
There was limited information about the sources used in the selection of treatment 
options. Only five studies reported consulting patients, carer organisations and/or experts, 
conducting literature reviews or using anecdotal evidence, in the construction and selection of 
treatment options (Caroli et al., 2011; Farrelly et al., 2014; Khan & Pillay, 2003; Levitan et 
al., 2015; Wilder et al., 2010).  
 
3.4. Study Results 
 In studies of preferred treatment delivery, participants reported a preference for home 
treatment (Crawford et al., 2004; Farrelly et al., 2004; Khan & Pillay, 2003). Among studies 
exploring preference for drug formulation (e.g. oral vs injectable antipsychotic medication), 
the results were inconclusive, with injections to be preferred over oral medication (Caroli et 
al., 2011), and with preference associated with medication adherence (Levitan et al., 2015) 
and with current formulation among patients on anti-psychotics (Patel et al. 2009). The main 
study findings, characteristics, and aspects of preference elicitation are described in Table 1. 
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Table 1. 
Summary of extracted data from the included studies. 
Study Population N 
Mean age 
Gender 
Ethnicity 
Design  Preferences as 
main objective 
(Y/N)  
 
Objective/s 
Categories 
presented for 
preference 
elicitation  
Preference 
elicitation method 
Main findings related to 
treatment preferences 
 
Sumner 
et al., 
2014 
 
UK 
Outpatients 
with non-
affective 
psychosis 
(ICD-10). 
 
 
 
N=90 
Mean age=37.22 
(19-63) 
 
Male (n=68) 
White (n=77) 
 
Mixed 
Methods- 
Sequential  
 
 
Yes 
 
Preferences over 
treatment 
interventions 
Treatment 
interventions: 
Treatment as usual 
(TAU), Self-Help 
manual with 
Telephone CBT and 
peer support, (SHT) 
& SHT plus Group 
support (SHG). 
 
 
 
 
Questionnaire 
involving closed 
and open-ended 
questions about 
patient preferences 
and the reasons for 
these.  
 
 
 
 
SHT was the most preferred 
option (43%), followed by 
preferred SHG (33%) and TAU 
(22%) 
Crawfor
d et al., 
2004 
 
UK 
Patients 
discharged 
from two 
mental health 
units. 
N=109 (74 of those 
had a diagnosis of a 
psychotic disorder) 
Mean age=41.2 
(SD= 15.4) 
 
Male (n=64) 
White (n=54) 
Black (n=25) 
Other (n=17) 
 
 
 
 
Exploratory 
- Cross-
sectional  
Survey  
Yes 
 
Preferences over 
the delivery of 
treatment  
Treatment 
setting/delivery: 
Home vs hospital 
vs community 
centre 
 
 
Short questionnaire, 
consisting of open 
and closed 
questions about 
compulsory 
treatment in 
different settings. 
48% preferred to be treated at 
home, 40% preferred hospital 
treatment and 13% preferred 
treatment in a community centre 
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Moritz 
et a.l,  
2017 
 
Germany 
Outpatients 
diagnosed 
with 
Schizophrenia. 
 
 
 
 
 
 
 
N=80 
Mean age=40.4 
(SD= 9.43) 
 
 
Male (n=30) 
Ethnicity not 
reported 
Exploratory. 
Cross-
sectional 
Survey  
Yes 
 
Preferences over 
treatment 
interventions 
Treatment 
interventions 
including 
psychological, 
medical, 
occupational, social 
etc. interventions. 
Online Survey 
including questions 
regarding patient 
experience with 
various 
interventions and a 
4-point Likert scale. 
 
 
 
Talking Therapy (M=3.18, SD= 
0.88) Psychoanalytic Therapy, 
(M=3.08, SD=1), Art Therapy 
(M=2.92, SD=1.04) & 
Metacognitive Training (MCT), 
(M=2.91, SD= 0.95) were 
appraised as the most helpful 
treatments. 
Farrelly 
et al., 
2014 
 
UK 
 
Outpatients 
with affective 
and non-
affective 
psychosis. 
 
 
N= 221 
Mean age=40.4 
(SD= 1.44) 
 
Male=51% 
White (n=63.5%) 
 Black (n= 23.5%) 
Other (n=13%) 
 
 
 
Qualitative. 
Thematic 
Analysis of 
JCPs 
 
(Part of an 
RCT) 
 
 
Yes 
 
Preferences over 
treatment 
interventions 
during a crisis 
or relapse 
 
Patients were 
presented with 
categories from a 
care plan ‘menu’ to 
select from. No 
further information 
was provided. 
JCPs, including 
items on preferred 
treatment 
interventions in a 
crisis or relapse.   
 
Most preferred option was home 
treatment team support (35% of 
the sample), followed by 
hospitalisation (19%) and 
medication changes (14%). 
Haddoc
k et al., 
2018 
 
UK 
Outpatients 
diagnosed 
with a 
Schizophrenia 
spectrum 
disorder (ICD-
10) 
 
 
N=89 (N=3 of 
which chose to be 
randomised) 
Mean age=36 
(SD=10.9) 
 
Male (n=60) 
White (n=76 ) 
BME (n=13) 
Mixed race (n=4) 
Not reported (n=2) 
Experimenta
l.  
PPT Trial 
Yes 
 
Preferences and 
outcomes of 
different 
methods of 
delivering CBT 
for psychosis. 
Preference to be 
randomised to a 
treatment 
intervention or not.  
 
Treatment 
Interventions 
included 
Treatment As Usual 
(TAU), TAU plus 
Telephone CBT & 
self-help manual 
(TS), High Support 
CBT (HS).  
 
 
Semi-structured 
Interview, including 
questions over 
which intervention 
they prefer, the 
strength of their 
preference (as 
measured by a 
Likert scale) and 
the reasons for their 
choice. 
TS was the most preferred 
option (33%), followed by TAU 
(31%), HS (22%), Not 
allocation (6%), and preference 
to be randomised (3%). 
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Mendel 
et al., 
2011 
 
Germany  
Inpatients 
diagnosed 
with 
Schizophrenia 
(ICD-10) & 
Multiple 
Sclerosis 
(MS). 
 
 
Schizophrenia 
(N=102) & MS  
(N= 101). 
 
M=36.5 (SD: 
11.42) 
 
Male (n= 56) 
Ethnicity not 
reported 
Experimenta
l. 
Randomised, 
Between 
groups 
design 
 
 
 
Yes 
 
Influence of 
physician’s 
advice and 
confidence 
(experimental 
condition) in 
patient’s advice 
taking and 
treatment 
preferences  
 
 
 
 
 
 
Hypothetical drugs 
(Drug A vs Drug B) 
that only differ in 
side-effects. 
 
 
 
 
 
Questionnaire 
describing a 
hypothetical 
decision scenario. 
Preferences were 
assessed pre and 
post clinician’s 
recommendation. 
 
 
 
Initial choice of patients with 
schizophrenia was Drug A 
(67%). But 48% of them later 
followed the advice of their 
doctor and chose the treatment 
option that was against their 
initial choice (e.g. Drug B) 
Huang 
et al., 
2011 
 
Taiwan 
 
Inpatients 
diagnosed 
with 
Schizophrenia 
(DSM-IV) 
 
 
 
N=55 
Mean age= 37.2 
(SD= 10.5) 
 
Male (n=22) 
Ethnicity not 
reported 
 
Cross-
sectional, 
questionnair
e study 
No 
 
Relationships 
between 
religion, 
psychopatholog
y with religious 
content, 
treatment 
preference and 
outcome 
 
Treatment 
Interventions: 
Psychiatric 
treatment vs 
religious 
intervention  
Semi-structured 
questionnaire, 
which included a 
‘Preference for 
Treatment Scale’. 
 
 
Patients with religious 
affiliation showed less 
preference toward psychiatric 
treatment (M=3.4, SD=0.8) than 
those without a religious 
affiliation (M=4.6, SD=0.8). 
 
More preference toward 
psychiatric treatment was 
predicted by lower religiosity 
score, higher satisfaction with 
psychiatric treatment and lower 
years of education (β=-0.077, 
P<0.001, F value = 11.562, 
Variance = 37%) 
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Levitan 
et al., 
2015 
 
 
US 
Outpatients 
with a self-
reported 
physician 
diagnosis of 
Schizophrenia. 
 
 
N=271 
M= 38.4 (SD= 
11.9) 
 
Male = 60% 
White = 73% 
 
 
Experimenta
l, DCE 
methodology 
Yes 
 
Judgements on 
important 
attributes of 
antipsychotic 
medication & 
preferences 
related to their 
risks & benefits. 
 
 
 
Hypothetical Drugs 
(Medication A vs 
Medication B) 
 
Preferences on the 
mode of 
administration & 
preferences related 
to risk & benefits of 
medication were 
inferred through the 
choices of drugs. 
 
 
 
 
 
 
Online Survey 
containing choice 
tasks, which 
involved selecting 
the ‘best’ 
hypothetical 
treatment for a 
hypothetical 
patient. 
 
 
 
 
 
 
Patients judged oral 
formulations to be better for 
adherent patients but judged a 
monthly injection to be better 
for non-adherent.  
 
Improvement in positive 
symptoms was the most 
important outcome (M=10) and 
hyperglycaemia was judged as 
the most important side effect 
(M=3.6) 
Wilder 
et al., 
2010  
 
US 
 
Outpatients 
diagnosed 
with affective 
and non-
affective 
psychosis, and 
psychotic 
depression. 
 
 
N= 123 (15 of 
which had 
psychotic 
depression) 
Mean age= 44.5 
(SD=9.9)  
 
Male (n=50) 
Caucasian (n=58) 
African American: 
(n=65)  
Longitudinal  
 
(Part of an 
RCT) 
Yes 
 
Medication 
preferences and 
associations 
with future 
prescription and 
adherence 
Patients were asked 
to identify 
medications they 
would request/or 
would refuse to 
take if they were in 
a crisis. There was 
no further 
information on the 
options presented. 
 
 
PADs. These 
included items on 
medication 
preferences and 
questions on 
preferred facilities 
& crisis 
interventions 
 
 
 
 
 
 
. 
Medications requested/ 
preferred:  
Valproate (25%), followed by 
risperidone (20%) and 
olanzapine (17%) 
Medications refused: 
Haloperidol (24%), followed by 
Lithium (23%). 
Medications prescribed: 
Risperidone (26%) followed by 
valproate (25%) 
 
Being prescribed a medication 
requested in the PAD predicted 
higher medication adherence. 
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Caroli et 
al., 2011 
 
France  
 
 
Outpatients 
diagnosed 
with 
schizophrenia  
 
 
N=206 
48% fell within the 
‘35-49’ age 
category 
 
Male= 65%  
Ethnicity not 
reported. 
Mixed 
Methods, 
survey study 
 
Yes 
 
Preferences 
(defined as 
opinions) 
regarding 
injectable 
medication 
Forms of 
medication:  
a) injections 
b) oral tablets  
c) drinkable 
solutions 
d) orally 
disintegrating 
tablets 
e) no preference  
 
 
Survey including 
medication options 
& open-ended 
questions to explore 
reasons for 
preferences. 
 
Injections were the most 
favoured dosage form (47%), 
followed by oral tablets (35%), 
drinkable solutions (7%) and 
orally disintegrating tablets 
(1%). 10% did not express a 
preference. 
 
Main reason: dosages were 
spread out over time (41%) 
Patel et 
al., 2009 
 
 
UK 
 
 
Outpatients 
with a 
diagnosis of 
schizophrenia 
or 
schizoaffectiv
e disorder 
(ICD-10) 
 
 
N=222 
39.1 % fell within 
the ‘45+’ age 
category  
 
Male (n= 143)  
White (n=110) 
Other (n=77)  
Not reported (n=35) 
Cross-
sectional, 
questionnair
e study 
Yes 
 
Attitudes 
towards 
antipsychotic 
medication, side 
effects, insight, 
and formulation 
preferences. 
 
Antipsychotic drug 
formulation: 
Oral vs depot vs no 
preference  
Questionnaire 
involving direct 
questions on 
formulation 
preference. 
 
 
 
 
Patients on orals expressed a 
preference for their current 
formulation (91.8%) whereas 
those on depot were generally 
indifferent (43.4% preferred 
depot, and 30.3% preferred 
tablets). 
 
 
 
 
 
Khan & 
Pillay, 
2003 
 
UK 
 
 
Outpatients 
diagnosed 
with 
Schizophrenia 
(ICD-10).  
 
 
N= 61 
Age Range: 16-65 
(Mean age not 
provided) 
 
Male (n=41) 
White Residents of 
the British Isles 
(n=26) 
South Asian (n= 
35) 
Cross-
sectional, 
comparative 
study 
Yes 
 
Preferences 
(defined as 
attitudes) 
towards home 
and hospital 
treatment in a 
crisis or 
emergency. 
Treatment Setting: 
Home vs Hospital 
Treatment 
Structured 
questionnaire, 
including questions 
about preferences 
and reasons for 
these, measured on 
a 5-point Likert 
scale.  
 
Both groups expressed 
preference for home treatment.  
Reasons for their preferences 
differed; for Asian respondents 
the main reasons were: stigma 
associated with hospitalisation 
(82.8%) & religious need 
(74.3%).  
Note. Descriptive & inferential statistics are provided where reported in studies. SD=Standard Deviation, M=Mean.  
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3.5. Study Quality  
Total scores and percentages as well as category scores per paper are presented in 
Appendix 1.5. Using Walsh and Downe’s (2006) criteria, the methodological quality of most 
studies was considered ‘good’, with only three studies (Khan & Pillay, 2003; Mendel et al., 
2011; Patel et al., 2009) being appraised as ‘acceptable’.  
All studies received four or five out of five for the Introduction and Discussion 
categories, and all but two studies (Caroli et al., 2011; Khan & Pillay, 2003) received four out 
of five for the Results category. Moreover, all but Khan and Pillay (2003) received four or 
five out of five for the Preliminaries category (defined as abstract, title, aims and style), 
whereas three studies scored less than four or five out of five in the Design category 
(Crawford et al., 2004; Khan & Pillay, 2003; Mendel et al., 2011). This indicates that most 
studies gave adequate summaries of current knowledge, had clear aims, used appropriate 
designs and interpreted clearly their results. 
Most studies received the lowest scores in the Sampling, Data Collection & Ethical 
Matters categories. In the Data Collection category, Patel et al., 2009 scored two out of five 
as there was limited information on the data collection methods used. Moreover, three studies 
scored two out of five in the Sampling category as they did not report their sampling methods 
(Crawford et al., 2004; Mendel et al., 2011; Sumner et al., 2014). Finally, three studies scored 
one or two out of five in the Ethical Matters category for not reporting their ethical approval 
or other ethical procedures (Huang et al., 2011; Khan & Pillay, 2003; Moritz et al., 2017).   
 
3.6. Weaknesses and Strengths of Preference Elicitation Methods  
Appendix 1.6 shows the strengths and weaknesses of the preference elicitation 
methods across studies. For the purposes of the synthesis, strengths and weaknesses were 
thematically organised into the following categories; a) quantitative, which included choice-
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based techniques (e.g. questionnaires with closed questions and discrete choice tasks) and 
rating techniques (e.g. Likert scales), and b) qualitative, which included the use of open-
ended questions and structured tools (i.e. advance statements) to elicit preferences in a 
meeting or interview with the researcher.  
Although most studies stated the limitations and strengths of their study design, 
justification for choosing the specific preference elicitation method was limited. When Likert 
scales were used, information on the psychometric properties of the scale was not provided. 
Moreover, although single questions were chosen as they provided a structured way to elicit 
and analyse preferences, they may have failed to identify wider elements of patient 
preference such as the individual’s perception about the treatment option and its attributes 
(Bowling & Rowe, 2005). This could lead to biased inferences about patient preferences and 
threat the validity of their choices.  
To address this, some studies used qualitative-based techniques; these were chosen as 
they allow the exploration of factors involved in patient’s choice and to ensure participants’ 
understanding of the treatments presented (Sumner et al., 2014). However, such techniques 
can make comparisons across participants difficult and they involve more time and resources 
as indicated by the JCP meetings, which required several key stakeholders to be present. 
Levitan et al. (2015) chose the DCE methodology to address such problems, as it can 
provide both information on the actual preference, as well as information on patients’ 
consideration of the treatment options’ attributes (Bridges et al., 2011a). However, as with 
most techniques involving evaluation of cognitive tasks, the authors reported that there could 
be difficulties when using these methods with individuals with psychosis due to high 
cognitive load which may affect task completion.   
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4. Discussion 
4.1 Results in context 
The primary aim of this review was to explore the way that patient preferences for the 
treatment of psychosis have been elicited in the literature. Consistent with previous reviews 
(McHugh et al., 2013; Ryan et al., 2001) our findings suggest that there is variation across 
studies in the methods used to assess preferences. This could be explained by the different 
objectives and questions posed across studies.  
Moreover, this study found that there was variation with regards to the types of 
treatments that were subjected to preference assessment, with most studies exploring 
preference for ‘formal’ treatment interventions (e.g. medical or psychological interventions). 
Similar to Lindhiem et al. (2014), our findings suggest that preferences were measured 
without providing information on treatment components, risks or benefits. Where information 
was provided, the content and format for disseminating this were not described. Such 
findings raise questions about the validity of participants’ choices and as to whether informed 
choices would differ, as provision of information could affect patient choices (Koedoot et al., 
2003).  
The second aim of the review was to explore the strengths and weaknesses of the 
preference elicitation methods.  Our findings indicate that among studies using quantitative 
methods, the measures used were easy to administer but were either non-validated or too 
simplistic. Qualitative methods provided richer information on patient choices but were more 
resource heavy.  DCE methodology was the only method involving both information on the 
preferred choice and on the trade-offs but required greater cognitive effort and active 
participation. However, it could be argued that active participation is a pre-requisite for all 
research involving individuals with psychosis and is, in fact, highlighted as a potential 
limitation in other studies (e.g. Farrelly et al., 2014; Wilder et al., 2010). Moreover, there is 
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evidence that patients with schizophrenia can meaningfully engage in discrete choice tasks 
and weight risks and benefits when making treatment choices (Bridges et al., 2011b). 
Furthermore, there are additional methodological limitations across the studies that 
could affect preference elicitation and thus, the validity of the choices made. These relate to 
the data collection (e.g. whether tasks were completed during face-to-face meetings with the 
researchers or online) and associated biases, such as the interviewer effect or the use of more 
educated and less representative sample. Furthermore, the use of hypothetical treatment 
alternatives across most of the studies could lead to biased results, as hypothetical preferences 
may differ from actual preferences. 
Overall, our findings suggest that there is variation across studies in relation to the 
methods used to elicit preferences and that there are strengths and weaknesses for each 
method.  This could be explained by the different objectives and questions posed across 
studies. In particular, where the objective of the study was to explore differences among 
participants in terms of a particular preference, researchers used quantitative methods, mainly 
questionnaires or surveys with closed questions. Conversely, when the focus was on the 
experiences of service users with a variety of treatments and on the reasons behind treatment 
preferences, studies used qualitative methods, such as semi-structured interviews, and open-
ended questions. This has clinical implications for future research, as variation should be seen 
as a function of the study’s purpose and as the difference in methodology could not 
necessarily reflect poorer study quality, but different objectives. Therefore, future studies 
should not only consider the advantages and disadvantages of each preference method, but 
also ensure that the method of their choice is in line with their objectives and the questions to 
be answered. 
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4.2. Limitations & strengths of the review 
This is the first review which has attempted to systematically describe and evaluate 
the strengths and weaknesses of the methodologies employed to elicit preferences for the 
treatment of psychosis.  Specifically, this review included studies conducted in various 
mental health systems and cultures and studies using various methodologies. However, the 
heterogeneity of methods, samples, and treatment interventions being assessed may limit the 
robustness of the conclusions that can be drawn. 
Moreover, although we aimed to only include studies with the highest methodological 
rigour (i.e. peer reviewed studies) the exclusion of unpublished studies might have limited the 
validity of our findings. Furthermore, due to the poor indexing of treatment preferences, a 
highly sensitive and specific retrieval was not feasible. However, we aimed to address this by 
consulting a librarian, by drawing on treatment preference literature and by conducting 
searches of a key journal in psychosis research.  
Finally, this review used an established tool and an independent rater to assess the 
quality of included studies at the full-text screening stage. However, due to time restraints 
additional ratings at different stages of the screening process were not conducted. Thus, this 
could have affected our review’s methodological rigour.   
 
4.3. Implications 
It has been proposed that systematic reviews on patient preferences should be 
considered when developing clinical guidelines (Lenert & Kaplan, 2000). The results of this 
review could be useful to authors of guidelines and policy makers, as they highlight the 
limitations and validity threats associated with non-standardized methods used to elicit 
preferences.  Our findings also suggest that patient preferences may not be well-informed and 
may not accurately portray patient choice. This has implications both for clinicians and 
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researchers, who should ensure that detailed information on treatment components, risks and 
benefits is provided prior to treatment selection to allow informed choices to be made 
(Dwight-Johnson, Unutzer, Sherbourne, Tang, & Wells, 2001). Moreover, researchers and 
clinicians should ensure that they not only provide full information prior to treatment 
selection, but also give service users the opportunity to share their experience with the 
researchers and determine their own preferences. This may be particularly important for 
fostering choice and autonomy, considering the lack of involvement in decision-making 
among individuals with psychosis (Schizophrenia Commission, 2012).  
This review concluded that there are various methodologies used to elicit preferences, 
with no one best method being identified. Specifically, our study highlighted the need for 
considering the aims and purpose of the study when deciding on which elicitation method to 
choose. For instance, studies aiming to explore service user choice of treatment as an 
outcome of their experiences with that particular treatment, or studies focusing on the reasons 
behind treatment preferences should use qualitative methods, whereas quantitative methods 
could be used when exploring differences in preferences.  
Furthermore, several of the included studies scored low in relation to their data 
collection procedures and lacked information on the specific techniques used. Researchers 
should pay attention to not just choosing the most appropriate method to answer their 
question, but to also rigorously conduct it.   
Finally, this review found differences in the way that studies operationalise treatment 
preferences, which could explain inconsistencies in their measurement. Despite this review’s 
preliminary recommendations, clearer guidance on how to conduct research on patient 
preferences for the treatment of psychosis is needed to allow for meaningful comparison of 
findings.  
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5. Conclusion 
Our findings suggest that from the variety of methods used to elicit treatment 
preferences, there is no single best method. Researchers should be encouraged to apply 
rigorous methods to elicit treatment preferences and clinical practice should be guided by a 
careful consideration of what constitutes a valid preference. Further research is required to 
include studies on different operationalisations of treatment preferences and to explore other 
methods used. 
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Plain English Summary 
 
Title: PRiorItieS: A study exploring PReferences for treatment, Internalised Stigma & Social 
Defeat among individuals in Receipt of care for Psychosis from Mental Health Services 
 
Background: Research suggests that individuals with psychosis have reduced access to 
evidence-based treatment. Moreover, migrants experience greater delays and inequalities in 
accessing care, which could explain the higher prevalence of psychosis in this group. Factors 
such as experiences of stigma, social defeat or preference for non-medical treatments could 
delay help seeking and increase the risk of developing psychosis, as symptoms remain 
untreated for longer. Understanding these factors is essential to improving prevention and early 
intervention strategies and increasing access to treatment. Developing a reliable measure of 
treatment preferences may help in this respect.  
 
Aims: The main aim of this study was to test the feasibility of recruiting individuals with 
psychosis to test out the validity and reliability of a new measure of treatment preferences – 
the Glasgow Mental Health Preferences Tool (GlasMPT). We also aimed to explore whether it 
is feasible to recruit migrants and non-migrants with experiences of psychosis to investigate 
differences on experiences of stigma, social defeat (the stress linked with the feeling of being 
an outsider), and treatment preferences between these groups.  
 
Methods 
 
1. Participants 
Participants were individuals with lived experience of psychosis, aged 18 and older, fluent in 
English and were receiving care from acute and rehabilitation services across NHS Greater 
Glasgow & Clyde (GG&C). Migrants needed to be staying legally in the UK for the past six 
months or have applied for asylum. 
 
2. Recruitment  
Phase 1. A panel including clinicians working with individuals with experiences of psychosis 
and service users involved in research commented on the suitability and clinical utility of the 
tool, prior to testing it out in clinical settings.  
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Phase 2. Staff identified eligible participants and informed them about the study. Those 
interested in participating met with the researcher who provided further information and 
obtained consent. Participants then completed the measures on social defeat, stigma and the 
GlasMPT. 
 
3. Design of study 
This was a feasibility study, and therefore the analysis used was exploratory in nature.     
 
4. Data collection 
Participants attended up to two sessions with the researcher to complete some brief 
questionnaires, the GlasMPT, which was administered via a card-sorting task, and a 
demographic form. All sessions took place in psychiatric wards. 
 
Main Findings: The study recruited 27 participants; only one migrant was recruited thus group 
comparisons were not conducted. The study showed that there are difficulties with recruiting 
migrants with psychosis. Verbal feedback from participants showed that the GlasMPT was 
useful and suggestions for improvement should be considered in future studies. Our study also 
found that participants preferred psychosocial interventions compared to medical or alternative 
types of treatment. We also found that those experiencing greater stigma also experienced 
greater social defeat. Future studies should build on these findings and test the tool with a 
bigger sample, comprising both of migrants and non-migrants, as our findings relating to the 
tool’s validity were mixed, and could have been affected by our small sample size.  
 
Key Reference: 
Cantor-Graae, E., & Selten, J. P. (2005). Schizophrenia and Migration: A Meta-Analysis and 
Review. American Journal of Psychiatry, 162 (1), 12-24. 
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Abstract 
Background:  Research suggests that migrants have reduced access to treatment for 
psychosis, and more prolonged pathways to care, which could increase their risk for 
developing psychosis. Factors such as internalised stigma, experiences of social defeat and 
preference for non-medical treatment could delay help seeking, thereby leading to the 
development of psychosis. 
Aims: Our primary aim was to pilot the feasibility of recruiting migrants and non-migrants 
with psychosis to test a new measure of treatment preferences. We also aimed to explore 
group differences on experiences of stigma, social defeat and treatment preferences. 
Methods: Twenty seven individuals in receipt of care for psychosis completed measures of 
social defeat, internalised stigma and the GlasMPT.  
Results: Difficulties with recruiting migrants are discussed. Results were also mixed with 
regards to the tool’s psychometric properties, indicating the need for further refinements and 
testing. Exploratory analysis suggested that most participants preferred psychosocial 
interventions for their problems, and greater stigma was associated with greater social defeat.  
Conclusion: Given the relationship between delays in help-seeking and development of 
psychosis, there is a need to understand barriers to help-seeking, particularly for those at risk, 
such as migrants. Future studies should draw on our findings to improve migrant recruitment 
and develop culturally sensitive measures of treatment preferences. 
Keywords: treatment preferences, psychosis, psychometrics, feasibility 
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1. Introduction 
There is a need to improve understanding of the factors that impede help-seeking for 
people with psychosis, given that there is reduced access to evidence-based treatments 
despite recommendations from clinical guidelines (Schizophrenia Commission, 2012; 
National Institute for Health and Care Excellence; NICE, 2014). Moreover, there is evidence 
of higher prevalence of psychosis in first and second-generation immigrants (Cantor-Graae & 
Selten, 2005), although the relationship between foreign migration and higher risk for 
developing psychosis remains ambiguous.   
Several hypotheses have attempted to explain this relationship, including the selective 
migration of predisposed individuals, the tendency of clinicians to misdiagnose schizophrenia 
in individuals of non-dominant ethnicity, or that pre- or peri-migratory exposure to trauma 
could account for the high incidence of psychosis in refugees (Leao et al., 2006; Ödegaard, 
1932; Sashidharan, 1993). 
More recently, research on pathways into care has demonstrated that some ethnic 
groups may experience significantly longer delays for accessing treatment (Thomson, Chaze, 
George & Guruge, 2015). Longer duration of untreated psychosis has been associated with 
poorer prognosis and treatment outcomes (Birchwood, Todd, & Jackson, 1998). While some 
delays occur because of failure of services in detecting psychotic prodromes (Etheridge, 
Yarrow & Peet, 2004), there is also a delay in seeking treatment in those who are already in 
contact with services when they develop psychotic symptoms (Norman, Malla, Verdi, Hassall 
& Fazekas, 2004).  
 It is possible that a range of risk factors are potentiated within the period between 
migration and the onset of recognised psychotic symptoms requiring care, which increases 
the risk for developing psychosis (Cantor-Graae, Pedersen, McNeil, 2003). Factors such as 
internalised stigma (i.e. when a person considers publicly held stereotypes to be self-
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relevant), experiences of social defeat post-migration (i.e. the stress produced after prolonged 
exposure to social adversity) and preference for non-medical treatments can contribute to 
delays in help-seeking, and thereby increase the risk for psychosis (Thomson et al., 2015). 
 In particular, ‘feeling different’ can often lead individuals to expect that others will 
judge them, which may result in hiding their difficulties and to delays in help-seeking 
(Gronholm, Thornicroft, Laurens & Evans-Lacko, 2017). Moreover, Cantor-Graae and Selten 
(2005) argue that prolonged exposure to social defeat experiences can lead to biased 
information processing.  Furthermore, stigma and discrimination have been linked with the 
development of a paranoid attributional style (Garety, Kuipers, Fowler, Freeman & 
Bebbington, 2001), which could subsequently generalise into psychotic symptoms. 
Experiences of discrimination are higher among migrants (Veling et al., 2007) and can also 
provoke feelings of inferiority and social exclusion, contributing in this way to a delay in 
help-seeking. Finally, migrants are more likely to approach religious leaders, faith healers or 
family members before seeking psychiatric help (Rathod, Kingdon, Phiri & Gobbi, 2010). 
This can extend the duration their symptoms remain untreated, and thus, increase the risk for 
psychosis.   
  Despite the impact of the above factors on help-seeking for psychosis, there are no 
studies that have investigated treatment preferences among migrants in receipt of care for 
psychosis in the UK. It is possible that a lack of appropriate measures could account for this. 
This study aims to develop a culturally sensitive and reliable measure that assesses treatment 
preferences in a more engaging way (i.e. via a card-sorting task). 
 
 
 
 
36 
 
1.1. Primary Objective 
1. To conduct a preliminary examination of the psychometric properties of a new 
measure of treatment preferences for individuals with experiences of psychosis – 
the Glasgow Mental Health Preferences Tool (GlasMPT)  
1.2. Secondary Objectives 
1. To explore the feasibility of recruitment of migrants and non-migrants with 
experiences of psychosis to investigate differences in treatment preferences, 
internalised stigma, and experiences of social defeat. 
2. To examine the relationships between treatment preferences, internalised stigma 
and social defeat within each sub-group  
2. Methods 
2.1. Design 
This was a cross-sectional, feasibility study comprised of two phases: 
Phase 1 involved the development of a measure of treatment preference, during which an 
expert panel provided feedback on the suitability and clinical utility of the tool. 
Phase 2 involved testing the tool in clinical settings and exploring the feasibility of recruiting 
migrants and non-migrants to explore differences in social defeat, stigma and treatment 
preferences.  
 
2.2. Participants 
Individuals were eligible if they had lived experience of psychosis and were receiving 
care from acute or long-term rehabilitation services in Greater Glasgow & Clyde (GG&C) 
health board area. Experience of psychosis involved participants with a diagnosis of 
schizophrenia spectrum disorder as defined by the ICD-10 (International Classification of 
Diseases of the World Health Organization; WHO, Tenth Edition), (WHO, 1992), as well as 
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participants who had not yet received a diagnosis but whose symptoms deemed severe 
enough to require treatment. Participants also needed to be over the age of 18 with 
conversational English language ability. Participants were excluded if they were not eligible 
for consent (e.g. if substance misuse, head injury or an organic disorder was the primary 
cause of psychotic symptoms). Participants who were acutely unwell or had a learning 
disability to the extent that it could affect their meaningful participation were also excluded.  
 For the non-migrant group, participants needed to be born in the UK and have British 
nationality, whilst for the migrant group participants needed to be first generation migrants, 
coming from Low And Middle Income Countries (LMIC) as per the World Bank’s 2019 
country classifications (Appendix 2.1), and staying in the UK legally or having applied for 
asylum. 
 
2.3. Measures 
The Glasgow Mental Health Preferences Tool (GlasMPT). 
The GlasMPT was developed to assess treatment preferences for psychosis. The 
measure consists of two packs of cards. One of the packs contains descriptions of different 
types of problems drawn from research on relapse prevention for psychosis (Birchwood, 
Spencer & McGovern, 2000) and is divided into three categories: problems with thinking, 
problems with feelings and problems with behaviour.  
The other pack describes different types of treatment and sources of help across a 
range of domains (e.g. medical, psychological, social and alternative treatments and sources 
of support). Blank problem and treatment cards were also included to allow participants to 
suggest other problems or treatment options not described in the tool. Appendix 2.2 provides 
a list of all the items included in the tool.  Participants’ answers and any comments related to 
the completion and acceptability of the tool were recorded in a card sort form (Appendix 2.3). 
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Participants were asked to select up to 15 cards describing the problems they would like most 
help with. They were then presented with the treatment cards and asked to choose the type of 
treatment(s) they would prefer to receive for each of the problem category they selected. 
Initial administration also involved ranking of the problem and treatment categories in terms 
of importance and preference, however this was later abandoned as pilot testing of the tool 
showed that it substantially increased the duration of the session (Appendix 2.4). 
 
The Internalised Stigma of Mental Illness Scale (ISMI; Ritsher, Otilingam, & Grajales, 
2003). 
This 29-item scale was used to measure internalised stigma. The measure has strong 
internal consistency (α = 0.90) and test–retest reliability (r = 0.92) (Ritsher & Phelan, 2004), 
and has been widely used in research (Boyd, Adler, Otilingam & Peters, 2014).  
 
The Social Entrapment and Defeat Scales (Gilbert & Allan, 1998).  
These two brief self-report questionnaires were used to measure experiences of social 
defeat. Both scales were administered as they are considered to assess the same construct and 
have demonstrated good psychometric properties (Taylor, Wood, Gooding, Johnson, & 
Tarrier, 2009).  
 
The General Help Seeking Questionnaire (GHSQ; (Wilson, Deane, Ciarrochi & Rickwood, 
2005). 
The GHSQ was used to assess the construct validity of the GlasMPT. The GHSQ was 
chosen as it is a flexible measure of intentions to seek help from different sources and for 
different problems, and treatment preferences, among others, reflect an individuals’ intention 
to seek help. The GHSQ has satisfactory reliability and validity (Wilson et al, 2005). 
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2.4. Procedure 
2.4.1. Phase 1: Development of the GlasMPT 
The GlasMPT items were generated through a multi-step process: 1) review of 
relevant measures and related papers; 2) use of the QUAID tool (Question-Understanding 
Aid; Graesser, Wiemer-Hastings, Wiemer-Hastings, & Kreuz, 2000b) to check the clarity and 
wording of provisional items; 3) online survey that gathered feedback from clinicians and 
experts by experience to ascertain the items’ clarity and relevance. 
Step 1 involved searching the literature for relevant papers that explored treatment 
preferences for psychosis (see Chapter 1 of the thesis). Initial steps also involved contacting 
authors of relevant studies to gather information on the development of their questionnaires. 
As this study aimed to target individuals from different ethnic backgrounds, we did not 
restrict the treatment items to ‘formal’ types of treatment (e.g. medical or psychological 
treatments) but decided to also include ‘informal’ sources of support such as religious healers 
or family and friends. The selection of these ‘informal’ types of help was based on studies on 
pathways to care for migrants with psychosis (Rathod et al., 2010).  
Following this, a pilot questionnaire was initially constructed to assess treatment 
preferences. The questionnaire listed different types of treatment and asked participants to 
rate on a Likert scale their experience with each treatment and how beneficial they perceived 
this treatment to be. However, due to difficulties with engaging this population in research 
(Cook, Chambers, Coleman & Hart, 2005), it was decided that a more engaging way to 
administer the measure was required. Thus, we drew on our clinical experience with 
individuals with psychosis, and in particular, on the development of relapse prevention plans, 
where a card-sort task can be used to allow individuals to actively participate in the 
identification of their ‘early warning signs’ of psychosis (Birchwood et al, 2000). These signs 
are conceptualised as ‘subtle changes in thought, affect and behaviour’ that precede a 
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psychotic episode and can be easily identified by patients (Birchwood et al, 2000).  Based on 
this, the content and the format of the GlasMPT was adapted to match that of the card-sort. 
Questions on experience were dropped to keep the measure brief and to simplify 
administration, and the final format consisted of a) problem cards (which were basically 
adaptations of the ‘early warning signs’ cards) and of b) treatment cards (which included 
items from pathways to care and conventional, ‘formal’ treatments). 
Step 2 involved testing the wording of items for clarity using the QUAID tool, a web-
based tool that assists in identifying potential problems in lay people comprehending the 
meaning of questions on questionnaires. The QUAID tool assessed the wording of the 
GlasMPT items across the following areas a) vague or imprecise or ambiguous terms b) 
complex syntax c) working memory overload (e.g. use of long sentences). Feedback from the 
QUAID suggested that the items were of adequate clarity and easy to comprehend by lay 
people.  
During Step 3 an expert panel, which included clinicians and experts by experience, 
completed an online survey to provide their views on the draft tool.  Clinicians were qualified 
mental health professionals working in the recruitment sites who agreed to act as local 
collaborators. Experts by experience were members of the University of Glasgow’s Psychosis 
Research Group and had also agreed to act as advisors for this study. The panel was 
presented with provisional items of the GlasMPT and asked to rate the clarity and relevance 
of each item on a 9-point Likert-scale. 
 
2.4.2. Phase 2: Validation of the GlasMPT & completion of questionnaires 
The researcher met with clinicians to provide information about the study (Appendix 
2.5) and answer any questions. Clinicians were asked to identify potential participants who 
met the eligibility criteria from their caseload and provide them with a study flyer (Appendix 
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2.6). Those who expressed an interest in the study were approached by the researcher to 
discuss the study and arrange a data collection session. Prior to data collection, participants 
were provided with participant information sheets (Appendix 2.7) and were asked to sign a 
consent form (Appendix 2.8) and complete a demographic form (Appendix 2.9).   
 
2.5. Sample size 
 As this was a feasibility study we aimed to provide information that can be used by 
future studies for power and sample size estimations (Lancaster, Dodd & Williamson, 2004) 
and therefore we performed no formal calculations. However, we aimed to recruit at least 12 
participants per group, as per Julious’s (2005) recommendation for feasibility studies or a 
total sample size of 30 (Billingham, Whitehead & Julious, 2013). 
 
2.6. Ethical approval 
 This study was approved by NHS West of Scotland Research Ethics Committee 
(Appendix 2.10) and the NHS GG&C Research and Development Department (Appendix 
2.11).  Responsible Medical Officers (RMOs) were also notified (Appendix 2.12). 
 
3. Results 
3.1. Recruitment 
  Of the 73 participants initially identified as eligible, 27 participants were included in 
the study. Fig. 1 illustrates the flow of participants. Feasibility data suggest that recruitment 
of individuals with psychosis was difficult, with only 55% of participants proceeding to the 
stages of written informed consent and data completion of all measures. As we only managed 
to recruit one migrant, comparisons on treatment preferences, stigma and social defeat 
between migrants and non-migrants were not conducted. 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
        
 
 
 
 
 
Fig. 1. Participant Flow  
 
3.2. Sample Characteristics 
The average age of participants was 38.96 years. 66.7% of the total sample were male 
and 74.1% identified as White British. Most common diagnosis was Paranoid Schizophrenia 
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(44.4%), and most participants were recruited from acute wards (88.9%). Table 1 illustrates 
participant characteristics for the total sample, including those who completed a sample of the 
measures.  Comparisons on the demographic characteristics between those who completed all 
questionnaires (n=25) and those who completed a sample (n=2) were not made, as the 
subsample were very small and non-completion was due to the patients being discharged 
before their second meeting with the researcher. 
Table 1. 
 Sample Demographics  
Gender (N, %) 
   Male 
 
18 (66.7 %) 
   Female 9 (33.3 %) 
Age (Mean, SD) (M=38.96, 12.12) 
Ethnicity (N, %)  
   White British 20 (74.1 %) 
   White Irish 2 (7.4 %) 
   White Other (Irish) 
   Asian Chinese 
   Asian Pakistani 
   Asian Other (Indian) 
1 (3.7 %) 
1 (3.7 %) 
2 (7.4 %) 
1 (3.7 %) 
Education (N, %)  
   No degree 23 (85.2 %) 
   Degree 4 (14.8 %) 
Religion/Belief (N, %) 
   No Religion 
   Christianity 
   Islam 
   Buddhism 
   Jehovah’s witness  
   Other (e.g. multireligious, humanist, nature) 
   Not reported 
Marital Status (N, %) 
    Married/civil partnership/cohabiting 
    Single 
    Divorced/separated 
Diagnosis (N, %) 
   Paranoid Schizophrenia 
   Schizoaffective Disorder 
    Brief/Acute Psychotic Episode 
    Psychosis NOS 
    No diagnosis/psychotic symptoms 
Level of Care/Setting (N, %) 
   Acute ward 
   Rehabilitation ward 
Mental Health Status (N, %) 
   Informal 
   Detained under MHA 
 
11 (40.7 %) 
7 (25.9 %) 
2 (7.4 %) 
1 (3.7 %) 
1 (3.7 %) 
4 (14.8 %) 
1 (3.7 %) 
 
2 (7.4 %) 
23 (85.2 %) 
2 (7.4%) 
 
12 (44.4 %) 
4 (14.8 %) 
4 (14.8 %) 
1 (3.7 %) 
6 (22.2 %) 
 
24 (88.9 %) 
3 (11.1 %) 
 
13 (51.9 %) 
14 (48.1 %) 
Note.  M = Mean/Median, SD = Standard Deviation. N = 27  
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3.3. Data Analysis Strategy 
 Second generation migrants (n=3) were not excluded from the analysis due to having 
British nationality. Their data, along with data from the one participant in the migrant group 
were pooled with those of the non-migrant group and included in the analyses. One item from 
the GHSQ, (item 10: ‘how likely is that you would seek help from anyone not listed above?’) 
was excluded, as most participants reported that it was not applicable and thus did not 
complete it.  Single missing items were limited (n<3) and were imputed using individual 
participant mean item scores on relevant questionnaires, following consultation with a 
statistician. Data were not included in the analysis when participants did not complete certain 
sections of the measures (i.e. when they did not identify any thinking problems). Finally, the 
assumptions of linearity and normal distribution of data were examined for all variables, and 
when violations were observed, non-parametric tests were used. 
 
3.4. Psychometric Properties of the GlasMPT  
3.4.1. Face Validity 
 Two clinical psychologists with 0-5 and >20 years of experience, and an expert by 
experience took part in the online survey between 2nd November and 14th December 2018.  
Four items (17.39%) in the ‘problem’ category and two (10%) in the ‘treatment’ category 
received an average rating between 5.6 and 7 (measured on a 9-point Likert scale). Although 
this suggests that the average clarity and relevance of the items were satisfactory, some of 
these items were eventually amended or excluded from the final version of the GlasMPT. An 
additional item, ‘Looking after myself, by doing something relaxing, such as listening to 
music or having a massage’, was also included to reflect the option of self-care. 
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3.4.2. Internal Consistency  
 Appendix 2.13 provides a summary of the internal consistency values for the Social 
Defeat, Entrapment, ISMI, GHSQ and GlasMPT measures. Hinton, Brownlow, McMurray, & 
Cozens’s (2004) classification was used to interpret the alpha values. 
 Cronbach’s alpha values for Social Defeat, Entrapment, ISMI & GHSQ ranged 
between .70 and .90 indicating that the scales and subscales of these measures showed ‘high 
to excellent’ reliability. For the GlasMPT problem cards, alpha values were calculated both 
overall and for each problem category (i.e. for emotional, thinking and behavioural 
problems), and ranged between .53 and .68, suggesting ‘moderate’ reliability. For the 
GlasMPT treatment cards, there were three alpha values calculated overall, each 
corresponding to treatments selected per problem category (i.e. all treatments selected for 
emotional problems, all treatments selected for thinking problems and all treatments selected 
for behavioural problems), as participants could select the same treatment cards for each 
problem category. These alpha values ranged between .61 and .77, indicating ‘moderate to 
high’ reliability. 
 Finally, alpha values for the GlasMPT treatment cards subcategories (i.e. the 
subcategory referring to the type of treatment selected for one problem category [e.g. 
‘Medical treatments selected for thinking problems’]) ranged between -.14 and .69, indicating 
‘low to ‘moderate’ reliability. 
 
3.4.3. Construct Validity 
 The two subscales of the GHSQ, the ‘Emotional Problems’ subscale and the ‘Suicidal 
Thoughts’ subscale, were used to assess whether participant’s intention to seek help for 
emotional and thinking problems would be correlated with their intention to seek help, as 
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expressed by their answers on the ‘Treatment for Feeling Problems’ and ‘Treatment for 
Thinking Problems’ categories of the GlasMPT. Participants’ answers on the GlasMPT were 
considered not only to reflect preference but also intention to seek treatment, as they were 
asked to choose the type of treatment they would like to receive for the problem they 
identified. The study found no significant association between the ‘Emotional Problem’ 
subscale of the GHSQ and the ‘Treatment for Feeling Problems’ category of the GlasMPT:  
τ(24) = .21, 95%BCA CI [-.16, .54], p>.05. Moreover, no significant association was found 
between the ‘Suicidal Thoughts’ subscale of the GHSQ with the ‘Treatment for Thinking 
Problems’ Subscale of the GlasMPT: τ(22) = -.10, 95%BCA CI [-.45, .26], p> .05.   
 
3.5. Main Findings  
3.5.1. Problems & Treatment Preferences 
The most frequent type of problem that participants selected were emotional 
(M=56.89%, SD= 22.75), followed by problems with their thinking (M=46.86%, SD= 25.59), 
and behavioural problems (M=39.4%, SD=25.18). Most participants selected psychosocial 
types of support and treatment (Table 2) for the problems they identified, with social support 
being their first choice (M=59.97%, SD= 8.37), followed by psychological interventions 
(M=51.17%, SD= 9.40).  
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Table 2.  
Percentages of treatment cards selected (out of all treatment types available) for each combination of problem category and type of treatment 
 Type of Treatment  
 Medical Psychological Alternative Social 
 % SD CI % SD CI % SD CI % SD CI 
Type of 
problem 
 
           
   -Thinking  
      N=24 
44.79 32.95 30.88-58.71 50 35.44 35.03-64.97 34.03 18.86 26.06-41.99 52.08                      40.32 35.06-69.11 
   - Feeling 
       N=24   
42.71 30.82 29.69-55.72 61.11 32.10 47.56- 74.67 36.59 20.06 27.92-45.27 68.75 32.35 55.09-82.41 
   -Behaviour 
       N=22 
37.5 29.63 24.36-50.64 42.42 32.82 27.87-56.98 34.85 23.37 24.48-45.21 59.09 39.75 41.47-76.72 
Mean 
percentage 
41.66 3.75 32. 33-50.99 51.17 9.40 27.82 -74.52 35.15 1.30 31.90 -38.40 59.97 8.37 39.18-80.76 
*Note. Type of treatment = medical, psychological, alternative, social. Medical treatment includes items such as seeing a doctor  or taking a tablet, psychological includes 
seeing a psychologist, relaxation etc., social refers to support from family or friends and alternative includes spiritual help, self-help or alternative therapies. Type of problem 
= thinking, feeling and behaviour, SD= standard deviation, CI= confidence intervals 95%, N= sample size used in analysis. 
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3.5.2. Within group associations  
Multiple bivariate correlations were used to examine the relationships between the 
key variables (treatment preference, internalised stigma and social defeat) within participants 
(Table 3). Non-formal treatments (i.e. alternative and social) were used in the analysis, given 
their potential to delay help-seeking (Thomson et al., 2015).  There were significant 
associations between participant’s scores on ISMI and social defeat scale, between 
entrapment and social defeat scores and between entrapment and ISMI. The results suggested 
that higher internalised stigma was associated with greater experience of social defeat and 
entrapment. Entrapment scores were also positively correlated with preferences for social 
support and treatment when participants identified emotional problems: the greater their 
feelings of entrapment, the more participants preferred to receive social support for their 
emotional problems. Moreover, participants’ preferences to receive social support when they 
identified problems with their thinking correlated positively with their preferences to seek 
alternative sources of support for their thinking problem. Finally, preference to receive 
alternative treatments when participants identified problems with their behaviour was 
positively correlated with their preference to get social support for the same problem.  
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Table 3. 
Sample sizes and correlations (Kendall’s τ or Pearson’s r) between Social Defeat & Entrapment Scales, ISMI and Non-Formal Treatments (Alternative & 
Social) selected per problem category in the GlasMPT. 
 
  Non-Formal Treatments (GlasMPT) 
Alternative Social 
Entrapment 
 
 
 
Defeat  
 
 
 
ISMI  
  
 
 
Thinking Thinking  
Feeling  Feeling  
Behaviour Behaviour  
 
 Coef., BCa CI, N Coef., BCa CI., N Coef., BCa CI, N Coef., BCa CI, N Coef., BCa CI, N 
Entrapment  
 
1 .73** [.49, .86] 27 .30* [.10, .66] 26  .04 [-.39, .44] 22 .06 [-.24, .38] 24 
.34 [.01, .61] 23 .37* [-.02, .69] 24 
.04 [-.32, .39] 22 .21 [-.12, .50] 22 
Defeat   1 .56** [.28, .76] 26 .06 [-.30, .39] 24 -.22 [-.49, .06] 24 
.005 [-.32, .35] 23 -.06 [-.43, .28] 24 
-.28 [-.59, .01] 22 -.21 [-.52, .12] 22 
ISMI  
 
 
Non-Formal Treatment (GlasMPT) 
  1 .29 [-.05,.62] 24 -.02 [-.33, .30] 24 
.01 [-.33, .35] 23 -.19 [-.54, .16] 24 
-.06 [-.36, .29] 22 
 
-.02 [-.34, .28] 22 
 
  Alternative       
     - Thinking  
 
  1 .42* [0.10, .72] 24 
     - Feeling               1 .23 [-17, .52] 23 
     - Behaviour                  1 .52** [.13, .82] 22 
  Social      
     -Thinking   
 
    1 
     - Feeling  1 
     - Behaviour                          1 
BCa bootstrap 95% Cls reported in brackets. N= sample size. *Correlation is significant at the .05 level (two tailed). ** Correlation is significant at the .01 level (two tailed)
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4. Discussion  
4.1. Recruitment & Retention 
 This study aimed to examine the feasibility of recruiting migrants and non-migrants 
with psychosis to test a new measure of treatment preferences and explore differences on 
preferences, social defeat and stigma. Similar to existing research (Yancey, Ortega & 
Kumanyika, 2006) this study failed to recruit an adequate number of migrants to allow for 
group comparisons.  Failure to recruit migrants was predominantly associated with lack of 
eligible participants in the recruitment sites.  Specifically, only four people met criteria for 
the migrant group (i.e. first-generation migrants from LMICs). Of these, one migrant was 
transferred to another ward, one agreed to take part and two refused to participate, suggesting 
that acute admission units were not the best place to recruit migrants and that recruitment 
could be possible if access to migrants was facilitated.  
 This is an important implication for future studies, which suggests researchers should 
liaise with clinicians to identify through preliminary discussions or clinical audits, the 
services that are most likely to be used by migrants. As pathways to care may be different for 
migrants (Thomson et al., 2015) future studies should consider involving participants from a 
variety of services (e.g. primary, secondary or inpatient services), and with non-traditional 
pathways (e.g. through criminal justice system, religious organisations or voluntary sector). 
Consideration should be also given to recruiting migrants from specialist trauma services, as 
trauma has been associated with elevated risk of psychosis (Bendall, Jackson, Hulbert & 
McGorry, 2008) and as migrants are likely to experience greater trauma (Leao et al., 2006). 
Moreover, the inclusion of second-generation migrants may also provide valuable 
information about their treatment preferences compared to those of non-migrants, as research 
suggests a higher prevalence of psychosis among second-generation migrants (Cantor-Graae 
& Selten, 2005) and less traditional pathways to care (Thomson et al., 2015).   
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 Although this study gained managerial approval to recruit from two psychiatric 
hospitals, patients allocated to Early Intervention Services in Psychosis (ESTEEM) within 
acute wards could not be approached, as additional approval from ESTEEM was not 
obtained. This could have affected recruitment, as feedback from clinicians confirmed that 
there was a high prevalence of migrant population within ESTEEM who met the eligibility 
criteria.  It may be that the challenges already faced by services to engage migrants in 
treatment (Ouellet-Plamondon, Rousseau, Nicole & Abdel-Baki, 2015) can lead services to 
take a protective approach towards migrants, where any risk of unsettling them (including 
participation to research) is avoided.  Future research should address this by liaising closely 
with services to provide information and reassurance, and by involving them in recruitment 
procedures so that the most efficient and least disruptive recruitment methods are identified. 
 Feasibility data highlighted that recruitment was also difficult for the non-migrant 
group. Several reasons, including the duration of the data completion, which lasted between 
25 and 75 minutes, time restraints, and participants’ mental state at point of approach by the 
researcher may have accounted for this. It is also likely that the nature of recruiting from 
acute wards, which involves a quick patient turnover, affected recruitment and participant 
retention. Future studies may benefit from a briefer assessment, more resources to facilitate 
frequent visits to the wards, and from following up participants in the community.  
 The higher recruitment rates in acute wards are probably related to participants being 
recruited from only one rehabilitation ward, with slower patient turnover, and patients with 
more chronic difficulties. Finally, lower recruitment rates were observed at start of 
recruitment. It is likely that this was related to recruitment being delayed due to difficulties in 
contacting ward managers to discuss recruitment, which resulted in having access to only two 
wards (one acute, and one rehab) for the first month of data collection. Subsequently a more 
assertive approach was undertaken which improved recruitment rates. Future studies should 
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factor in systemic factors, such as staffing issues or sickness, and use alternative approaches 
to liaise with services to improve communication and recruitment. 
 
4.2. Main Findings 
 Our findings suggest that although the expert panel felt that the GlasMPT included 
relevant items, the data showed poor construct validity, raising questions about whether the 
operational definition that was chosen (i.e. intention to seek help) was reflecting the true 
theoretical meaning of treatment preferences. It is possible that a tool with a different 
operationalisation of treatment preferences could provide different results. It is also likely 
that the small sample size and the existence of outliers which were included in the analysis, 
affected our results. 
 Despite this, Cronbach alpha coefficients suggest ‘moderate to high’ internal 
consistency for the problem cards and the treatment cards when alpha values were calculated 
as an overall (i.e. when all sub-categories and sub-types of treatments and problems were 
included in the analysis). However, when analysis was conducted for each subcategory of 
treatments, alpha values reduced, with one value being negative, suggesting that removal of 
certain items was required. However, this could be explained by fewer observations being 
included in subcategory analysis and thus internal reliability being distorted by extreme 
values. Future studies should consider refining the tool by making the necessary amendments 
highlighted by the analysis. 
 Preliminary analysis of treatment preferences suggested that psychosocial types of 
treatment were the most preferred treatment options. This is consistent with previous research 
on treatment preferences for psychosis which indicated that patients preferred psychosocial 
types of treatment over medical treatments (Moritz, Berna, Jaeger, Westermann & Nage, 
2017). 
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 Moreover, our study found that within participants, those who experienced greater 
stigma also experienced greater experiences of entrapment and social defeat. This is not 
surprising, as experiences of stigma and discrimination could lead to a sense of social defeat, 
making individuals feel inferior and less worthy. Our findings also suggest that the greater 
their feelings of entrapment, the more participants preferred to receive social support for their 
emotional problems and that the more social support sources they selected for their thinking 
problems the more alternative types of treatment they also wished to receive.  Finally, 
participants’ preferences to receive alternative treatments when they identified problems with 
their behaviour was positively correlated with their preferences to get social support for the 
same problem. Although this study did not explore reasons for preferences, it is likely that 
non-formal treatments are perceived as more beneficial than medical treatments due to the 
risks associated with these (e.g. poor efficacy and side effects of medication; Farrelly et al., 
2014), or due to previous negative experiences with mental health services, which could lead 
to a lack of confidence in services to treat patients effectively (Rathod et al., 2010).  
 An additional limitation was that the sample was too small to perform meaningful 
subgroup analysis on demographic variables and treatment preferences; future studies should 
account for this by exploring potential differences.  
 
4.3. Strengths and Limitations 
 Despite the recruitment difficulties, every effort was made to facilitate data collection 
by including participants with comorbid difficulties (who did not meet exclusion criteria) and 
allowing for adjustments to be made when required (e.g. reading through the material for an 
individual with visual impairment). Including participants with comorbidities could have 
affected our findings by introducing confounding bias; however, comorbidities are common 
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among individuals with psychosis (Buckley, Miller, Lehrer & Castle, 2009), indicating that 
our sample is likely to be representative of the actual population.  
 This study recruited 27 participants, in line with the recommended sample size (i.e. 
30) for feasibility studies (Billingham et al., 2013).  Furthermore, this study was the first to 
explore treatment preferences for psychosis using a structured, comprehensive and culturally 
sensitive tool in the UK. The development of this measure was guided by research on relapse 
prevention (Birchwood et al., 2000) and literature on pathways to care for migrants with 
psychosis (Thomson et al, 2015). We aimed to make the tool sensitive to individual 
background, culture and beliefs about the origins of mental illness. Thus, this tool was the 
first, to our knowledge, to have included ‘formal’ (i.e. medical, psychological) and ‘informal’ 
interventions (i.e. social support and alternative therapies) as treatment options in this area.    
 Moreover, the format and administration of the tool via a card-sorting task aimed to 
increase participation by making the data collection process more interactive and engaging.  
Anecdotal feedback from participants is that they found the tool useful, relevant to their 
experiences, and thought provoking. They also reported an increased awareness over the 
sources of help and support that were either already available to them or that they could 
access. Nonetheless, participants also highlighted areas for improvement, such as the 
reduction of items to make the sessions shorter, or inclusion of additional options, such as 
phoning a help-line, or not using any help. Such feedback should be taken into consideration 
when refining the tool. Moreover, future studies may benefit from including a qualitative 
component to capture patient views in a more structured way. 
 Finally, there was some variation in terms of how service users interacted with the 
assessment, with some participants being interested in volunteering additional information. 
For instance, some participants wished to explain how their experience with the treatments 
they had received had influenced their preferences, or wished to discuss ways that services 
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could improve to meet the needs of patients with various preferences. Although such 
knowledge has not been formally captured, service users have provided some helpful 
information about how the tool could be further refined to include exploration of aspects of 
treatment that they have found beneficial. Moreover, the interaction of service users with the 
task was also noted to be different depending on where they were in their recovery journey at 
the time of the assessment, or their mental health status (e.g. whether they were detained or 
not). Future studies will benefit from taking account of these user-experience factors to help 
refine preference assessment tools. 
 
5. Conclusions  
 More research on the refinement of the GlasMPT is needed, as our findings suggest 
some sound psychometric properties despite poor construct validity. Future studies should 
consider whether adding a qualitative component or a different mode of administration (e.g. 
questionnaire) may improve the tool’s validity and reliability. Further testing with a bigger 
sample comprising of migrants and non-migrants is also needed, as patient preferences may 
vary significantly across ethnicities. 
 Our study highlighted difficulties in recruiting migrants. However, it has provided 
useful information to help future studies improve recruitment. Finally, we found a preference 
for psychosocial treatments among non-migrants. Although it is unknown to what extent such 
preferences relate to those of migrants, clinicians should be aware of this and attempt to 
incorporate patient preferences in treatment planning to increase engagement and up-take of 
evidence-based treatment.  
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video or animation material is directly usable, please provide the files in one of our 
recommended file formats with a preferred maximum size of 50 MB. Video and animation 
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files supplied will be published online in the electronic version of your article in Elsevier 
Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' 
with your files: you can choose any frame from the video or animation or make a separate 
image. These will be used instead of standard icons and will personalize the link to your 
video data. For more detailed instructions please visit our video instruction pages at 
http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be 
embedded in the print version of the journal, please provide text for both the electronic and 
the print version for the portions of the article that refer to this content.  
Supplementary data  
Elsevier accepts electronic supplementary material to support and enhance your scientific 
research. Supplementary files offer the author additional possibilities to publish supporting 
applications, high-resolution images, background datasets, sound clips and more. 
Supplementary files supplied will be published online alongside the electronic version of 
your article in Elsevier Web products, including ScienceDirect: 
http://www.sciencedirect.com. In order to ensure that your submitted material is directly 
usable, please provide the data in one of our recommended file formats. Authors should 
submit the material in electronic format together with the article and supply a concise and 
descriptive caption for each file. For more detailed instructions please visit our artwork 
instruction pages at http://www.elsevier.com/artworkinstructions 
RESEARCH DATA 
This journal encourages and enables you to share data that supports your research publication 
where appropriate, and enables you to interlink the data with your published articles. 
Research data refers to the results of observations or experimentation that validate research 
findings. To facilitate reproducibility and data reuse, this journal also encourages you to share 
your software, code, models, algorithms, protocols, methods and other useful materials 
related to the project. 
Below are a number of ways in which you can associate data with your article or make a 
statement about the availability of your data when submitting your manuscript. If you are 
sharing data in one of these ways, you are encouraged to cite the data in your manuscript and 
reference list. 
Data linking  
If you have made your research data available in a data repository, you can link your article 
directly to the dataset. Elsevier collaborates with a number of repositories to link articles on 
ScienceDirect with relevant repositories, giving readers access to underlying data that gives 
them a better understanding of the research described.  
There are different ways to link your datasets to your article.  
When available, you can directly link your dataset to your article by providing the relevant 
information in the submission system. For more information, visit the database linking page . 
For supported data repositories a repository banner will automatically appear next to your 
published article on ScienceDirect.  
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In addition, you can link to relevant data or entities through identifiers within the text of your 
manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 
734053; PDB: 1XFN).  
Mendeley Data 
This journal supports Mendeley Data, enabling you to deposit any research data (including 
raw and processed data, video, code, software, algorithms, protocols, and methods) 
associated with your manuscript in a free-to-use, open access repository. Before submitting 
your article, you can deposit the relevant datasets to Mendeley Data. Please include the DOI 
of the deposited dataset(s) in your main manuscript file. The datasets will be listed and 
directly accessible to readers next to your published article online.  
For more information, visit the Mendeley Data for journals page. 
Data statement  
To foster transparency, we encourage you to state the availability of your data in your 
submission. This may be a requirement of your funding body or institution.  
If your data is unavailable to access or unsuitable to post, you will have the opportunity to 
indicate why during the submission process, for example by stating that the research data is 
confidential. The statement will appear with your published article on ScienceDirect. For 
more information, visit the Data statement page.  
3D Neuroimaging 
You can enrich your online articles by providing 3D neuroimaging data in NIfTI format. This 
will be visualized for readers using the interactive viewer embedded within your article, and 
will enable them to: browse through available neuroimaging datasets; zoom, rotate and pan 
the 3D brain reconstruction; cut through the volume; change opacity and color mapping; 
switch between 3D and 2D projected views; and download the data. The viewer supports 
both single (.nii) and dual (.hdr and .img) NIfTI file formats. Recommended size of a single 
uncompressed dataset is ≤100 MB. Multiple datasets can be submitted. Each dataset will have 
to be zipped and uploaded to the online submission system via the ‘3D neuroimaging data’ 
submission category. Please provide a short informative description for each dataset by filling 
in the ‘Description’ field when uploading a dataset. Note: all datasets will be available for 
downloading from the online article on ScienceDirect. If you have concerns about your data 
being downloadable, please provide a video instead. For more information see: 
http://www.elsevier.com/3DNeuroimaging 
Policy and ethics. The work described in your article must have been carried out in 
accordance with The Code of Ethics of the World Medical Association (Declaration of 
Helsinki) for experiments involving humans; http://www.wma.net/e/policy/b3.htm and with 
the internationally accepted principles in the care and use of experimenta l animals. This must 
be stated at an appropriate point in the article. 
References 
Citation in text 
Please ensure that every reference cited in the text is also present in the reference list (and 
vice versa). Any references cited in the abstract must be given in full. Unpublished results 
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and personal communications are not recommended in the reference list, but may be 
mentioned in the text. If these references are included in the reference list they should follow 
the standard reference style of the journal and should include a substitution of the publication 
date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 
'in press' implies that the item has been accepted for publication. 
Web references 
As a minimum, the full URL should be given and the date when the reference was last 
accessed. Any further information, if known (DOI, author names, dates, reference to a source 
publication, etc.), should also be given. Web references can be listed separately (e.g., after the 
reference list) under a different heading if desired, or can be included in the reference list. 
Reference management software 
This journal has standard templates available in key reference management packages 
EndNote (http://www.endnote.com/support/enstyles.asp) and Reference Manager 
(http://refman.com/support/rmstyles.asp). Using plug-ins to word-processing packages, 
authors only need to select the appropriate journal template when preparing their article and 
the list of references and citations to these will be formatted according to the journal style. 
Responsibility for the accuracy of bibliographic citations lies entirely with the authors. 
Text: All citations in the text should refer to: 
1. Single author: the author's name (without initials, unless there is ambiguity) and the year 
of publication; 
2. Two authors: both authors' names and the year of publication; 
3. Three or more authors: first author's name followed by 'et al.' and the year of publication. 
Citations may be made directly (or parenthetically). Groups of references should be listed 
first alphabetically, then chronologically. 
Examples: "as demonstrated (Allan, 1996a, 1996b, 1999; Allan and Jones, 1995). Kramer et 
al. (2000) have recently shown ...." 
List: References should be arranged first alphabetically and then further sorted 
chronologically if necessary. More than one reference from the same author(s) in the same 
year must be identified by the letters "a", "b", "c", etc., placed after the year of publication. 
Examples: 
Reference to a journal publication: 
Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2000. The art of writing a scientific article. 
J. Sci. Commun. 163 (2) 51-59. 
Reference to a book: 
Strunk Jr., W., White, E.B., 1979. The Elements of Style, third ed. Macmillan, New York. 
Reference to a chapter in an edited book: 
Mettam, G.R., Adams, L.B., 1999. How to prepare an electronic version of your article, in: 
Jones, B.S., Smith , R.Z. (Eds.), Introduction to the Electronic Age. E-Publishing Inc., New 
York, pp. 281-304. 
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Journal names should be abbreviated according to the List of serial title word abbreviations: 
http://www.issn.org/services/online-services/access-to-the-ltwa/ 
Preparation of electronic illustrations and services  
General points 
•Always supply high-quality printouts of your artwork, in case conversion of the electronic 
artwork is problematic. 
•Make sure you use uniform lettering and sizing of your original artwork. 
•Save text in illustrations as "graphics" or enclose the font. 
•Only use the following fonts in your illustrations: Arial, Courier, Helvetica, Times, Symbol. 
•Number the illustrations according to their sequence in the text. 
•Use a logical naming convention for your artwork files, and supply a separate listing of the 
files and the software used. 
•Upload all illustrations as separate files. 
•Provide captions to illustrations separately. 
•Produce images near to the desired size of the printed version. This journal offers electronic 
submission services and graphic files can be uploaded via the online submission system. 
A detailed guide on electronic artwork is available on our 
website:http://authors.elsevier.com/artwork/schres 
You are urged to visit this site; some excerpts from the detailed information are given here. 
Formats 
Regardless of the application used, when your electronic artwork is finalised, please "save as" 
or convert the images to one of the following formats (Note the resolution requirements for 
line drawings, halftones, and line/halftone combinations given below.):•EPS: Vector 
drawings. Embed the font or save the text as "graphics". 
•TIFF: Colour or greyscale photographs (halftones): always use a minimum of 300 dpi. 
•TIFF: Bitmapped line drawings: use a minimum of 1000 dpi. 
•TIFF: Combinations bitmapped line/half-tone (colour or greyscale): a minimum of 500 dpi is 
required. 
•DOC, XLS or PPT: If your electronic artwork is created in any of these Microsoft Office 
applications please supply "as is". 
Please do not: 
•Supply embedded graphics in your word-processor (spreadsheet, presentation) document; 
•Supply files that are optimised for screen use (like GIF, BMP, PICT, WPG); the resolution is 
too low; 
•Supply files that are too low in resolution; 
•Submit graphics that are disproportionately large for the content. 
Captions 
Ensure that each illustration has a caption. Supply captions on a separate sheet, not attached 
to the figure. A caption should comprise a brief title (not on the figure itself) and a 
description of the illustration. Keep text in the illustrations themselves to a minimum but 
explain all symbols and abbreviations used. 
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Colourful e-Products 
Figures that appear in black & white in print appear in colour, online, in ScienceDirect at 
http://www.sciencedirect.com. There is no extra charge for authors who participate.  
For colour reproduction in print, you will receive information regarding the costs from 
Elsevier after receipt of your accepted article. Please indicate your preference for colour in 
print or on the Web only. Because of technical complications, which can arise by converting 
colour figures to "grey scale" (for the printed version should you not opt for colour in print) 
please submit in addition usable black and white versions of all the colour illustrations. For 
further information on the preparation of electronic artwork, please see 
http://authors.elsevier.com/artwork/schres 
AudioSlides  
The journal encourages authors to create an AudioSlides presentation with their published 
article. AudioSlides are brief, webinar-style presentations that are shown next to the online 
article on ScienceDirect. This gives authors the opportunity to summarize their research in 
their own words and to help readers understand what the paper is about. More information 
and examples are available at http://www.elsevier.com/audioslides. Authors of this journal 
will automatically receive an invitation e-mail to create an AudioSlides presentation after 
acceptance of their paper. 
Proofs 
When your manuscript is received by the Publisher it is considered to be in its final form. 
Proofs are not to be regarded as 'drafts'. 
Authors should keep a copy of their manuscript files as proofs will be sent to them without 
the original manuscript. One set of page proofs in PDF format will be sent by e-mail to the 
corresponding author, to be checked for typesetting/editing. No changes in, or additions to, 
the accepted (and subsequently edited) manuscript will be allowed at this stage. Proofreading 
is solely your responsibility. A form with queries from the copyeditor may accompany your 
proofs. Please answer all queries and make any corrections or additions required. The 
Publisher reserves the right to proceed with publication if corrections are not communicated. 
Return corrections within two days of receipt of the proofs. Should there be no corrections, 
please confirm this. Elsevier will do everything possible to get your article corrected and 
published as quickly and accurately as possible. In order to do this we need your help. When 
you receive the (PDF) proof of your article for correction, it is important to ensure that all of 
your corrections are sent back to us in one communication. Subsequent corrections will not 
be possible, so please ensure your first sending is complete. Note that this does not mean you 
have any less time to make your corrections, just that only one set of corrections will be 
accepted.  
Offprints 
The corresponding author, at no cost, will be provided with a PDF file of the article via e-
mail. The PDF file is a watermarked version of the published article and includes a cover 
sheet with the Journal cover image and a disclaimer outlining the terms and conditions of use. 
Additional paper offprints can be ordered by the authors. An order form with prices will be 
sent to the corresponding Author. 
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Appendix 1.2. Search Strategy 
 
Database Keywords 
Medline via 
OVID 
1. (Measur* or assess* or evaluat* or explor* or identif* or investigat* or elicit* or 
scale* or tool* or survey* or interview* or questionnaire* or focus group*).ti,ab,kw.  
2. (Psychosis or Psychoses or Psychotic* or schizo*).ti,ab,kw.   
3. ((Treat* or Patient* or Client*) adj2 (Prefer* or Priorit*)).ti,ab,kw.   
4. psychotic disorders/ or schizophrenia/   
5. patient satisfaction/ or patient preference/   
6. data collection/ or interviews as topic/ or "surveys and questionnaires"/ or health 
care surveys/ or self-report/   
7. 1 or 6   
8. 2 or 4   
9. 3 or 5   
10. 7 and 8 and 9   
11. limit 10 to (english language and yr="2000 -Current") 
EMBASE 
via Ovid 
1. (Measur* or assess* or evaluat* or explor* or elicit* or identif* or investigat* or 
scale* or tool* or survey* or interview* or questionnaire* or focus group*).ti,ab,kw.  
2. (Psychosis or Psychoses or Psychotic* or schizo*).ti,ab,kw.   
3. ((Treat* or Patient* or Client*) adj2 (Prefer* or Priorit*)).ti,ab,kw.   
4. psychosis/ or schizophrenia/   
5. patient preference/ or patient attitude/  
6. data collection method/ or interview/ or questionnaire/   
7. 2 or 4   
8. 1 or 6   
9. 3 or 5   
10. 7 and 8 and 9 
CINAHL via 
EBSCOhost  
S1:  TI ( Psychosis OR Psychoses OR Psychotic* OR schizo* OR schizophrenia 
spectrum disorder) OR AB ( Psychosis OR Psychoses OR Psychotic* OR schizo* OR 
schizophrenia spectrum disorder ) OR KW ( Psychosis OR Psychoses OR Psychotic* 
OR schizo* OR schizophrenia spectrum disorder ) 
S2: TI ( Measur* OR assess* OR investigat* OR evaluat* OR explor* OR elicit* OR 
identif* OR scale* OR tool* OR interview* OR focus group* OR questionnaire* OR 
survey* ) OR AB ( Measur* OR assess* OR investigat* OR evaluat* OR explor* OR 
elicit* OR identif* OR scale* OR tool* OR interview* OR focus group* OR 
questionnaire* OR survey* ) OR KW ( Measur* OR assess* OR investigat* OR 
evaluat* OR explor* OR elicit* OR identif* OR scale* OR tool* OR interview* OR 
focus group* OR questionnaire* OR survey* ) 
S3: TI ((Treat* or Patient* or Client*) N2 (Prefer* or Priorit*)) OR AB ((Treat* or 
Patient* or Client*) N2 (Prefer* or Priorit*)) OR KW ((Treat* or Patient* or Client*) 
N2 (Prefer* or Priorit*)) 
S4: (MM "Attitude Measures") OR (MM "Questionnaires") OR (MM "Scales") OR 
(MH "Research Instruments") OR (MM " Interview Guides") OR (MM "Data 
Collection Methods") 
S5: (MH "Psychotic Disorders") OR (MH "Schizophrenia") 
S6: (MM "Patient Preference") 
S7: S2 OR S4 
S8: S1 OR S5 
S9: S3 OR S6 
S10: S7 AND S8 AND S9      
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PsycINFO 
via 
EBSCOhost 
S1: TI ((Treat* or Patient* or Client*) N2 (Prefer* or Priorit*)) OR AB ((Treat* or 
Patient* or Client*) N2 (Prefer* or Priorit*)) OR KW ((Treat* or Patient* or Client*) 
N2 (Prefer* or Priorit*)) 
S2: TI ( Measur* OR assess* OR investigat* OR evaluat* OR explor* OR elicit* OR 
identif* OR scale* OR tool* OR interview* OR focus group* OR questionnaire* OR 
survey* ) OR AB ( Measur* OR assess* OR investigat* OR evaluat* OR explor* OR 
elicit* OR identif* OR scale* OR tool* OR interview* OR focus group* OR 
questionnaire* OR survey* ) OR KW ( Measur* OR assess* OR investigat* OR 
evaluat* OR explor* OR elicit* OR identif* OR scale* OR tool* OR interview* OR 
focus group* OR questionnaire* OR survey* ) 
S3: TI ( Psychosis OR Psychoses OR Psychotic* OR schizo*) OR AB ( Psychosis OR 
Psychoses OR Psychotic* OR schizo* ) OR KW ( Psychosis OR Psychoses OR 
Psychotic* OR schizo* ) 
S4: De Psychosis or DE Schizophrenia 
S5: DE Client Attitudes OR DE Client Satisfaction OR DE Preference Measures 
S6: DE Measurement OR DE Surveys OR DE Questionnaires OR DE Likert Scales 
OR DE Interviews 
S7: S3 OR S4 
S8: S2 OR S6 
S9: S1 OR S5 
S10: S7 AND S8 AND S9 
Psychology 
and 
Behavioural 
Sciences 
Collection 
via by 
EBSCOhost 
S1: TI ((Treat* or Patient* or Client*) N2 (Prefer* or Priorit*)) OR AB ((Treat* or 
Patient* or Client*) N2 (Prefer* or Priorit*)) OR KW ((Treat* or Patient* or Client*) 
N2 (Prefer* or Priorit*)) 
S2: TI ( Measur* OR assess* OR investigat* OR evaluat* OR explor* OR elicit* OR 
identif* OR scale* OR tool* OR interview* OR focus group* OR questionnaire* OR 
survey* ) OR AB ( Measur* OR assess* OR investigat* OR evaluat* OR explor* OR 
elicit* OR identif* OR scale* OR tool* OR interview* OR focus group* OR 
questionnaire* OR survey* ) OR KW ( Measur* OR assess* OR investigat* OR 
evaluat* OR explor* OR elicit* OR identif* OR scale* OR tool* OR interview* OR 
focus group* OR questionnaire* OR survey* ) 
S3: TI ( Psychosis OR Psychoses OR Psychotic* OR schizo*) OR AB ( Psychosis OR 
Psychoses OR Psychotic* OR schizo* ) OR KW ( Psychosis OR Psychoses OR 
Psychotic* OR schizo* ) 
S4: DE "PSYCHOSES" OR DE "SCHIZOPHRENIA" 
S5: DE "PATIENT satisfaction" 
S6: DE "RESEARCH methodology" OR  DE "INTERVIEWING" DE 
"QUESTIONNAIRES" 
S7:  S3 OR S4 
S8: S1 OR S5 
S9: S2 OR S6 
S10: S7 AND S8 AND S9 
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Appendix 1.3: Crowe Critical Appraisal Tool (CCAT) Form (v1.4) 
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Appendix 1.4: Data Extraction Form 
 
Data Extraction Form 
General/study characteristics                                                                                Study ID: _____ 
• Paper Title _______________________________________________________________________ 
• First author_______________________________________________________________________ 
• Publication year ___________________________________________________________________ 
• Origin of study (country) ____________________________________________________________ 
• Design ___________________________________________________________________________ 
• Method of Analysis ________________________________________________________________ 
• General Study Focus (exploratory, experimental) ________________________________________ 
• Objective(s) (Main, Secondary) 
__________________________________________________________________________________
__________________________________________________________________________________ 
• Outcomes (Primary, Secondary) 
__________________________________________________________________________________
__________________________________________________________________________________ 
Assessment of Bias 
• Funding (fully, partly, etc.) & source ___________________________________________________ 
Population Characteristics  
• Condition/Diagnosis ________________________________________________________________ 
• Mean Age ________________________________________________________________________ 
• Gender distribution ________________________________________________________________ 
• Ethnicity distribution _______________________________________________________________ 
• Setting (in-/outpatient) _____________________________________________________________ 
• Sample size (including drop outs, treatment & control group sizes) __________________________ 
__________________________________________________________________________________ 
• Sampling approach ________________________________________________________________ 
 
Aspects of the preference elicitation  
• Definition of treatment preferences 
__________________________________________________________________________________
__________________________________________________________________________________ 
• Preference elicitation method(s) 
__________________________________________________________________________________
__________________________________________________________________________________ 
• Categories/options presented for preference elicitation (e.g. choose between treatment 
interventions /treatment attributes/health states/health domains/other)  
__________________________________________________________________________________
__________________________________________________________________________________ 
• Psychoeducation (i.e. if information was provided about the treatment options/decision-support 
tool used prior to choice) 
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__________________________________________________________________________________
__________________________________________________________________________________ 
• Sources used in option selection, construction of tool and/or development of methodology (e.g. 
systematic reviews, experts/clinicians, patients/focus groups, family members, staff etc.) 
__________________________________________________________________________________
__________________________________________________________________________________ 
• Purpose of the preference elicitation (e.g. Efficacy of intervention/benefit to individual patients, 
research prioritisation, other) 
__________________________________________________________________________________ 
 
Results  
• Most preferred choice(s): 
__________________________________________________________________________________
__________________________________________________________________________________ 
• Other Key Findings  
__________________________________________________________________________________
__________________________________________________________________________________ 
• Strengths of elicitation method 
__________________________________________________________________________________
__________________________________________________________________________________ 
• Limitations of elicitation method 
__________________________________________________________________________________
__________________________________________________________________________________ 
• Comparisons of preferences among different sub-groups (Was sub-group analysis performed & 
what are the results for each subgroup? (if applicable) 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________ 
• Correlations between patient preferences and demographic variables (if applicable) 
__________________________________________________________________________________
__________________________________________________________________________________ 
 
Additional Notes  
 
 
 
 
 
 
 
 
 
 
 
 
Add Quality Rating (CCAT score) _______________________________________________________ 
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Appendix 1.5: Quality Appraisal of included studies 
 
 
Study 
CCAT Scores 
Prelimina
ries  
Introduction Design Sampling Data 
Collection 
Ethical 
Matters 
Results Discussion Total Total % 
Sumner et al., 2014 5/5 
 
4/5 
 
4/5 
 
2/5 
 
4/5 
 
3/5 
 
4/5 
 
5/5 
 
31/40 
 
78% 
Crawford et al., 2004 4/5 5/5 3/5 2/5 3/5 4/5 4/5 5/5 30/40 75% 
Moritz et al,. 2017 5/5 
 
4/5 
 
4/5 
 
3/5 
 
4/5 
 
2/5 
 
4/5 
 
4/5 
 
30/40 
 
75% 
Farrelly et al., 2014 4/5 
 
5/5 
 
4/5 
 
3/5 
 
4/5 
 
4/5 
 
4/5 
 
5/5 
 
34/40 
 
85% 
Haddock et al., 2018 5/5 5/5 5/5 4/5 4/5 4/5 4/5 5/5 37/40 93% 
Mendel et al., 2011 4/5 4/5 3/5 2/5 3/5 4/5 4/5 4/5 28/40 70% 
Huang et al., 2011 4/5 5/5 4/5 4/5 3/5 1/5 4/5 5/5 30/40 75% 
Levitan et al., 2015 5/5 
 
4/5 
 
4/5 
 
5/5 
 
4/5 
 
4/5 
 
4/5 
 
5/5 
 
35/40 
 
88% 
Wilder et al., 2010 4/5 
 
5/5 
 
4/5 
 
3/5 
 
4/5 
 
4/5 
 
4/5 
 
4/5 
 
32/40 
 
80% 
Caroli et al., 2011 5/5 5/5 4/5 4/5 4/5 4/5 3/5 4/5 33/40 83% 
Patel et al., 2009 4/5 5/5 4/5 3/5 2/5 3/5 4/5 4/5 29/40 73% 
Khan & Pillay, 2003 3/5 4/5 3/5 3/5 4/5 2/5 3/5 4/5 26/40 65% 
79 
 
Appendix 1.6: Table illustrating strengths and weaknesses of preference elicitation method per study design 
 
 
 Preference Elicitation Method Strengths 
 
Weaknesses 
 
Q
u
a
n
ti
ta
ti
v
e 
C
h
o
ic
e
 
b
a
se
d
 t
e
c
h
n
iq
u
e
s 
Simple, choice-based, closed questions 
(as part of a questionnaire/survey) 
Structured questions help to ensure 
comparability of responses and facilitate 
analysis 
 
May fail to capture the complex nature 
of preferences  
Decision- making scenarios & discrete 
choice tasks  
(e.g. DCE, Vignettes etc) 
The decisional situation is preference 
sensitive.  
 
DCE tasks can provide information on 
the trade-offs  
Evaluating cognitive tasks can be 
cognitively difficult for patients with 
schizophrenia  
R
a
ti
n
g
 
te
c
h
n
iq
u
e
s 
 Likert Scales (separate or as part of a 
questionnaire/structured interview) 
Relatively easy to complete 
 
Allow for measuring the strength of 
preference 
Non-validated measures 
 
 
Q
u
a
li
ta
ti
v
e 
S
tr
u
c
tu
r
e
d
 
in
te
r
v
ie
w
-b
a
se
d
 
te
c
h
n
iq
u
e
s 
Advance Statements  
(e.g. JCPs or PADs) 
The information generated may be richer 
& more clinically relevant  
 
They provide a more formal way to elicit 
and clearly document treatment 
preferences 
Lengthy process which requires high 
levels of motivation from participants.  
 
The involvement of clinicians in the 
completion may limit free expression 
of preferences  
 
Open-ended questions (as part of a 
questionnaire/structured interview) 
Ensure participants’ understanding and 
allow clarification of reasons for their 
choices. 
More difficult to compare responses 
across participants and facilitate 
analysis of preferences. 
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Appendix 2.1:  LMIC List  
World Bank Country Classification 2019 
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Appendix 2.2: GlasMPT Items (Problem & Treatment Cards) 
The wording of items was checked for clarity using the QUAID tool (Question-
Understanding Aid; Graesser, Wiemer-Hastings, Wiemer-Hastings, & Kreuz, 2000b), a web-
based tool that assists in identifying potential problems in lay people comprehending the 
meaning of questions on questionnaires. The following tables included the items that were 
included in the final version of the GlasMPT.  
Problem Items 
Thoughts Feelings Behaviours 
 P.1 - Hearing Voices P.7- Experiencing strange 
sensations 
P.16 - Spending too much time 
alone 
 P. 2 - Thinking people are 
against you 
P.8 - Feeling helpless  P.17 - Not leaving the house 
P.3 - Having difficulty 
concentrating 
P.9 - Feeling anxious or restless P.18 - Having difficulty sleeping 
or staying asleep  
P.4 -Seeing things others 
cannot see 
P.10 - Feeling tired or lacking 
energy 
P.19 - Neglecting your 
appearance 
P.5 - Worrying that other 
people can control your 
thoughts 
P.11 - Feeling irritable P.20 Feeling like not eating or 
eating more than you used to 
P.6 - Thinking that other 
people can read your mind or 
you can read theirs 
P.12 - Feeling sad or low P.22 – Drinking or smoking 
more 
P.21 - Having difficulty making 
decisions 
P.13 - Feeling guilty   P.23- Getting into arguments 
 P.14 - Feeling forgetful or 
distractible  
 
 P.15 - Feeling like you cannot 
trust other people 
 
 
Graesser, A.  C.,  Wiemer-Hastings, K., Wiemer-Hastings,  P.,  & Kreuz,  R. (2000).  The  
Gold Standard  of  Question  Quality  on  Surveys:  Experts,  computer  tools,  versus  
statistical indices.  In Proceedings of the American Statistical Association Section on 
Survey Research Methods. American Statistical Association, 459-464. 
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Treatment Items 
Medical Psychological Alternative  
(self-care, spiritual & alternative 
therapies) 
Social 
 T.1 - Taking 
tablets/pills 
T.8 - Talking to a 
psychologist about the 
problem 
T.6 - Seeing a faith healer T.2 - Talking to a 
friend 
T.4 - Seeing a 
doctor 
T.14 - Using relaxation 
techniques 
T.7 - Seeing a priest or imam T.3 - Getting support 
from my family 
 T.5 - Going 
to the 
hospital 
T.18 - Learning more 
helpful ways to cope 
with the problem, by 
changing my thoughts, 
feelings and behaviours 
 T.9 - Using natural remedies such as 
vitamins & herbs 
 
T.13 - 
Receiving 
ECT 
  T.10 - Exercising  
  T.11 - Having a healthy diet  
  T.12- Working or being busy  
  T.15 – Meditating  
   T.16 - Wearing lucky charms   
  T.17 - Praying or reading a religious 
book 
 
  T.19 - Aromatherapy: using aromatic 
oils to improve my mood/relax 
 
  T.20 - Acupuncture/needle therapy  
  T21 - Looking after myself or doing 
something relaxing (e.g. massage or 
listening to music) 
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Appendix 2.3:  Card Sort Form 
Card Sorting Task – Record Form 
Start:  ________          Subject ID: ___________ 
End:   ________ 
 
Thinking  
Cards  
 
 
Treatment  
 
(*for all  cards in 
‘thinking’ category) 
Feeling  
Cards 
Treatment 
 
(*for all  cards in 
‘feeling’ category) 
Behaviour 
Cards  
Treatment 
 
(*for all  cards in 
‘behaviour’ 
category) 
1.  
 
 
 1.   1.   
2.  
 
 
2.  2.  
3.  
 
 
3.  3.  
4.  
 
 
4.  4.  
5.  
 
 
5.  5.  
6.  
 
 
6.  6.  
7.  
 
 
7.  7.  
8.  
 
 
8.  8.  
9.  
 
 
9.  9.  
10.  
 
 
10.  10.  
11.  
 
 
 
11.  11.  
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12.  
 
 
12.  12.  
13.  
 
 
13.  13.  
14.  
 
 
14.  14.  
15.  
 
 
15.  15.  
 
 
Comments: 
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Appendix 2.4: Administration Guidelines & Procedure 
 
General guidelines for administration of the GlasMPT are as follows: 
 
Prior to commencing the administration process, it is essential that adequate time is spent 
to build rapport with the service user. This can be facilitated through relating in a warm and 
empathic manner with the service user and through adopting an open and curious stance 
when exploring their views.  
 
 Ideally, the task should flow like a conversation and the participant should be praised for 
their engagement and the effort they are putting in. This will help maintain rapport and 
maintain participant’s motivation.  
 
To ensure that the participant’s safety is maintained, the researcher should not ignore 
difficult emotions that may arise, when engaging in the task. The researcher should spend 
some time to explore these feelings with the participant and provide validation and support. 
The researcher can also offer the participant a break to allow them to manage these feelings 
prior to continuing with the task. If the participant experiences extreme distress the 
researcher should allow the participant to discontinue and direct them to agreed sources of 
support.  
 
The researcher should also explore any worries that may arise during the task and should 
address these appropriately. The participants should be reminded that the purpose of the 
task is to explore their treatment preferences and that this is not a test, nor there is a right or 
wrong answer.  
 
If, following this, participants struggle to complete the task, then the researcher should 
allow them to stop.  
 
After the task is completed, the researcher should offer the participant some time to go 
through any questions or worries the participants may have. As above, the researcher should 
ensure that any strong emotions or concerns are discussed prior to the participant leaving 
the room. 
 
 
Administration Instructions 
 
Prior to reading out the following instructions, the researcher should ensure that all 
material (problem cards, treatment cards & pens) are placed on the table or desk.  
 
 “In this task, we are going to use two packs of cards. One pack describes different 
types of problems that people may experience. The other pack describes different 
types of treatments that people would like to get to address their problems. 
 As you can see, there are also some blank problem and treatment cards (show the 
participant the cards). You can use these cards, to write down any other problems 
you may experience and/or any other types of treatment that you would like to get 
that are not listed in the cards.  
 First, I would like you to take a look at the problem cards and pick the ones which 
describe the problems you would like most help with.  
 Put the cards you have selected on this side of the table, and the cards you don’t 
need here (show the participant where to lay the cards). 
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 You can select up to 15 problem cards. 
(Once the cards are selected the researcher counts the cards and ensures that the 
participant is happy with their choices).  
 Great. Now, if we look at the cards you selected, we can see that these problem 
cards, can be divided into 3 main categories, a) problems with your feelings, b) 
problems with your thinking and c) problems with your behaviour (i.e. what you do or 
don’t do). 
 Now I am going to show you the treatment cards. Again, I would like you to take a 
good look at these cards. For each of the 3 categories of the problem cards you have 
picked, I would like you to choose at least one treatment card which describes the 
type of treatment that you would like to get to address the problems in each category. 
 You can pick two or more treatment cards for one problem category if you wish.  
 
 
*Initially, participants were also asked to rank the problem & treatment cards in order of 
importance. The guidelines were: 
 
Guidelines for the ranking of problem cards, (following selection of problem cards): 
 Now, I would like you to rank the cards in each category, in order of importance, by 
putting the most important problem for you at the top of each category and the least 
important at the bottom of the list (demonstrate an example if needed) 
Guidelines for the ranking of treatment cards,(following selection of treatment cards): 
 Now, I would like you to rank the treatment cards in each category, in order of 
importance, by putting the most important treatment for you at the top of each 
category and the least important at the bottom of the list (demonstrate an example if 
needed) 
 
 
However, these guidelines were eventually omitted as they increased substantially the 
duration of the session.  
 
Troubleshooting: 
 
Check that the participant understands the task and answer any questions that they have.  
 
Check if the participant requires assistance with reading or writing and if so, make sure 
you provide assistance (i.e. reading the cards to them and/or writing on the blank cards on 
their behalf). 
 
Let the participant know that you will be taking notes during the procedure to ensure that 
you write down their answers. 
 
If the participant does not understand or is not familiar with a particular term written in the 
cards (e.g. a name of treatment) the researcher should provide a few examples to the 
participants.  
 
 
 
87 
 
Appendix 2.5:  Staff Information leaflet 
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Appendix 2.6: Study Flyer 
 
 
90 
 
 
Appendix 2.7: Participant Information Sheet 
 
                                    
 
A study exploring PReferences for treatment, Internalised Stigma & social defeat among  
individuals in receipt of care for psychosis from mental health services (PRiorItieS) 
 
Participant Information Sheet  
 
Invitation to Participate in a Research Project 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
 
Who is conducting the research?  
The research is being carried out by Foteini Thriskou who is a Clinical Psychologist in 
training from the University of Glasgow. The research is being supervised by Professor 
Hamish McLeod from the University of Glasgow. The NHS field supervisor is Dr Danielle 
Graham, a Clinical Psychologist who works for NHS Greater Glasgow and Clyde. 
 
What is the research about? 
This study is designed to improve understanding of mental health help-seeking preferences 
among people who are currently receiving care via NHS Greater Glasgow and Clyde. This 
research will help mental health services to develop better ways of helping people to get the 
help they need. The study is being undertaken by Foteini Thriskou as part of the 
requirements for a Doctorate in Clinical Psychology at the University of Glasgow.  
 
Who is being asked to take part?  
We are asking people who are currently being treated by mental health services in NHS 
Greater Glasgow & Clyde, and who also have experience of psychosis and other similar 
disorders, to take part in the study. 
 
Why I have been asked to take part in this study? 
A member of the mental health team responsible for your care (e.g. Consultant 
Psychiatrist, Clinical Psychologist or CPN) has suggested that you might meet the eligibility 
criteria for the study and could be interested in participating. 
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What are you asking me to consent to?  
If you consent, you will initially meet with a researcher to discuss the study. If, following this, 
you are still willing to take part, you will meet with the researcher at the service you attend to 
complete some measures about your experiences and help-seeking preferences.  This 
session is expected to last for approximately half an hour. 
You are also being asked to consent to your case notes being reviewed by one of the 
researchers to collect some relevant information about yourself such as your age, ethnicity, 
diagnosis etc. 
 
What does taking part involve?  
If you have expressed your interest in participating in the study, this means that:  
 You have given permission to the clinician who approached you, that your name and 
contact details can be passed to Foteini Thriskou (researcher) so that she can 
contact you to discuss the study. 
 During your first meeting with Foteini, she will give you more information about the 
study and answer any questions you may have.  
 If you remain willing to take part, you will book a convenient time to meet again with 
Foteini to complete some brief measures. The measures will ask you questions about 
your experiences and your mental health seeking preferences. 
 During the research session, before you start completing the measures, you will be 
will be asked to sign a consent form.  
 You will be able to take breaks during the sessions if you would like to, and you can 
decide to stop participating in the study at any time. You don’t have to give a reason 
for this.   
 If you need to travel to the service to meet with Foteini, the cost of you travelling there 
by public transport may be reimbursed for by funds from the University of Glasgow. 
Please speak to Foteini about this, as some restrictions may apply. 
 Your responses will be anonymous – any personal information that could identify you 
will be removed from the results of the study. 
 If answering the questions produces any distress, you will be offered help with 
managing this.  
 Following your participation, you will be given the opportunity to ask any further 
questions you may have about the research, and discuss any concerns that may 
arise after the session.   
 
Do I have to take part in this study?  
No, participation in the study is entirely voluntary. If you do not wish to take part you do not 
have to. Your decision whether to take part or not will not affect any treatment you receive.  
 
Can I change my mind?  
Yes. You can change your mind and withdraw from the study at any time, and you do not 
need to give a reason. Your care will not be affected in any way if you change your mind. 
 
Will my information be confidential? 
Yes. The information you provide will be treated confidentially and kept safe and anonymous. 
This means that your name will not be attached to any questionnaires, instead a participant 
number will be assigned. Your name and any information that could identify you will not 
appear in any reports and your answers to questions will not be used to inform your 
relationship with your mental health worker.  
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The anonymised questionnaires along with the consent forms and other study data will be 
stored in a password-protected computer on University of Glasgow premises and will be 
accessible only to the researchers who are directly involved with the research. Study data 
may be also looked by representatives of the study Sponsor, NHS Greater Glasgow and 
Clyde, to ensure the study is being conducted correctly. In particular, NHS Greater Glasgow 
and Clyde is the sponsor for this study based in Scotland. They will act as the data controller 
for this study for the information you provide and the information gathered from your medical 
records. This means that they are responsible for looking after your information and using it 
properly and are bound by the same confidentiality rules as the researchers and your care 
team.) 
 
With your permission we will also inform your responsible clinician and/or mental health team 
that you are taking part in the study. If you share information that makes the researcher 
concerned for your safety or the safety of other people, we may be required to tell others 
involved in your care (e.g. your keyworker or psychiatrist). We will always make a reasonable 
attempt to discuss this with you beforehand and explain why we are concerned. 
 
How long will you keep information? 
 
NHS Greater Glasgow and Clyde will keep identifiable information about you for up to 1 year 
after the study has finished. Your rights to access, change or move your information are 
limited, as we need to manage your information in specific ways in order for the research to 
be reliable and accurate. If you withdraw from the study, we will keep the information about 
you that we have already obtained. To safeguard your rights, we will use the minimum 
personally-identifiable information possible. 
 
You can find out more about how we use your information at 
http://www.nhsggc.org.uk/patients-and-visitors/faqs/data-protection-privacy/ 
 
 
What are the benefits of taking part? 
Although there are no direct benefits, we hope that taking part in this study may help improve 
service options for other people with similar experiences in the future.  
 
Is there a downside of taking part? 
Although we do not expect you to become distressed by your participation in the study, it is 
possible that completion of some questionnaires may stir up some unwanted emotions. If 
you have any concerns about taking part, you can contact Foteini, Hamish or discuss this 
with your key-worker or a member of your mental health team in order to access suitable 
support. There is also a debrief form within the pack which provides the contact details of 
supportive agencies should you require it.  
 
What will happen to the results of the study?  
The results of the study will be reported in Foteini Thriskou’s thesis as part of her Doctorate 
in Clinical Psychology degree. The results may also be published in scientific journals or 
presented at conferences.  
 
You will not be identified in any report or publication. You are welcome to receive a copy of 
the findings once the project is complete. Please tell Foteini if you would like this and provide 
an address to which a summary of the results can be sent to. 
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Who has reviewed the study? 
The study has been reviewed by the University of Glasgow to ensure that it meets standards 
of scientific conduct. It has also been reviewed by the Research and Development 
Department in NHS Greater Glasgow and Clyde and by the West of Scotland NHS Research 
Ethics Committee to ensure that it meets standards of ethical conduct. 
 
Can I speak to someone who is not involved in the study? 
Yes. You can speak to Dr Karen McKeown (Tel: +44 (0)141 211 3932 & 
Karen.McKeown@glasgow.ac.uk) or Professor Tom McMillan (Tel: +44 (0)141 211 0354 & 
Thomas.McMillan@glasgow.ac.uk), who have reviewed the study but are not involved in the 
study.  
 
What will happen if there is a problem or if I want to make a complaint? 
If you have any concerns about the study, please contact the researchers who will do their 
best to assist you:  
 
Researchers Contact Details 
Professor Hamish McLeod  
Professor of Clinical Psychology, Doctorate in 
Clinical Psychology Programme Director & 
Honorary Consultant Clinical Psychologist 
 
Mental Health & Wellbeing,  
University of Glasgow  
Administration Building, 1st Floor  
Gartnavel Royal Hospital  
1055 Great Western Road  
Glasgow G12 0XH  
Email: Hamish.McLeod@glasgow.ac.uk  
 
Foteini Thriskou 
Trainee Clinical Psychologist  
 
Mental Health & Wellbeing,  
University of Glasgow  
Administration Building,  
1st Floor  
Gartnavel Royal Hospital  
1055 Great Western Road  
Glasgow G12 0XH  
Email: f.thriskou.1@research.gla.ac.uk  
 
 
If you remain unhappy with the conduct of the study and wish to complain formally, you can 
do this through NHS Greater Glasgow and Clyde NHS Complaints by telephoning 0141 201 
4500 and/or 0141 287 0130 , or by emailing complaints@ggc.scot.nhs.uk.  
If you feel distressed following your participation in this study, you can speak to your key 
worker: .................................................................................................................................. 
 
Thank you for taking the time to read this 
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Appendix 2.8: Participant Consent Form 
                                                   
Participant Consent Form 
A study exploring PReferences for treatment, Internalised Stigma & social defeat among individuals 
in receipt of care for psychosis from mental health services (PRiorItieS) 
 
Chief Investigator:   Professor Hamish McLeod 
Researcher:    Foteini Thriskou 
Local Lead Investigator:  Dr Dannielle Graham 
 
                    Please initial the box 
 
1. I confirm that I have read and understand the Participant Information Sheet, dated…………….     
 (Version ….) for the above study. 
 
2. I have had the opportunity to ask questions, and I am satisfied with the answers I received.  
 
3. I have received enough information about the study. 
 
4. I understand that my participation is voluntary, and that I am free to withdraw at any time.   
I understand that I can do so without giving any reason, and without my care being affected. 
 
5. I understand that the researcher will keep the completed questionnaires and notes of my   
answers. I understand that all personal data will be anonymized and stored in locked drawers  
and will be destroyed following completion of analysis.  
 
6. I also understand that the study data may be looked by representatives of the study sponsor,  
NHS Greater Glasgow & Clyde, to ensure the study is being conducted correctly.  
 
7. I agree that fully anonymized data may be used in publications and other materials arising 
from the study. 
 
8. I understand that if I become upset during the research session the researcher will help me to  
access appropriate professional support if this is required. 
  
9. I understand that if I say anything that makes the researcher concerned about my safety or  
the safety of another person this information may be communicated to a third party.  
 I also understand that the researcher will attempt to discuss this with me beforehand.  
 
10. I agree that my RMO, Psychiatrist, Key Worker and/or my Mental Health Team will be 
informed of my participation in the study.   
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11. I understand that a member of the research team will examine my case notes to obtain 
some personal data such as information about my age, diagnosis, ethnicity etc.  
 
11. I agree to take part in the study. 
 
13.    I would like to receive a copy of the study results and these can be sent to me   
         via email at __________________________ or at the following address:  
_____________________________________________________________________________ 
_____________________________________________________________________________ 
         
 
 
 
Participant Name              Date    Signature 
 
………………………   … / … / ……  ……………………. 
 
Researcher                Date     Signature 
 
………………………   … / … / ……  ……………………. 
 
 
 
     
 
    1 copy for participant; 1 copy for researcher 
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Appendix 2.9: Demographic Form 
       
 
       PRiorItieS; A study exploring PReferences for treatment, Internalised Stigma & social  
defeat among individuals in receipt of care for psychosis from mental health services 
 
Participant Demographic Form  
 
 
1. Participant Number: ___________                       Group: Migrant / Non-migrant 
 
2. Site:    Leverndale /Gartnavel/ ESTEEM/ Other: ___________          
    
3.  Level of Care:  Acute/ Rehab / Early Intervention 
 
4. Gender:   Male / Female / Prefer not to state 
 
5. Age:  _____________ 
 
6. Country of birth: _________________ 
 
7. Is English First language?      Y/N                                          
 
8. Has participant received a diagnosis of a psychotic disorder?       Y/N 
(Please state type of psychotic disorder or relevant symptoms the participant is presenting with) 
_________________           
 
For the migrant group: 
 
Has participant been living in the UK for the past 6 months?       Y / N 
 
Is the participant an asylum seeker?      Y/N 
 
For those participants admitted in acute or rehab wards:  
 
Date of Admission: ________________ 
 
Is the participant detained under any Mental Health Act Section?  Y / N 
(If yes, please state under which section the patient is detained) ______________________________ 
 
 
9. Ethnicity:  
 
White British               Black African    Asian Chinese 
White Irish                       Black Caribbean    Asian Indian 
White other (please state) ________     Black other (please state) _________ Asian Pakistani 
          Asian other (please 
state) ________ 
Mixed White & Asian      
Mixed White & Black African 
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Mixed White & Black Caribbean 
Mixed other (please state) _________       Prefer not to state 
 
10. Marital status: 
 
Divorced/Civil Partnership Dissolved    Married/Civil Partnership/Common Law 
Separated       Other (please state) ____________ 
Single       Prefer not to state 
Widowed 
 
 
11. Religion/Belief: 
 
Atheism    Islam     No Religion  
Buddhism   Jehovah's Witness  Other (please state) ____________ 
Hinduism   Judaism    Prefer not to state 
Sikhism  
Christianity (Please indicate denomination) ______________________ 
 
12. Years of formal education (& associated qualifications): 
 
< 6/7 years  
7-9 years  
10-13 years (e.g. high school or college diploma or secondary education diploma such as A Levels) 
14-16 years (e.g. graduate degree) 
16-18 (e.g. postgraduate degree such as Masters) 
19+ years (e.g. PhD or other Doctoral level degree) 
 
 
 
Please consider also the following exclusion criteria prior to proceeding to data collection:  
 
Is the participant under the influence of any substances that would affect meaningful participation in 
the study? Y/N 
 
Has the participant had a brain injury that would affect meaningful participation in the study? Y/N 
 
Does the participant have a learning disability that that would affect meaningful participation in the 
study? Y/N  
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Appendix 2.10: Research Ethics Committee approval  
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Appendix 2.11: Research and Development Department Approval 
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Appendix 2.12: Notification letter to Responsible Medical Officer 
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Appendix 2.13: Reliability Analysis (Internal Consistency of Scales) 
The following table summarizes the internal consistency (Cronbach’s alpha) values for the Social 
Defeat, Entrapment, ISMI, GHSQ and GlasMPT, presented overall (where applicable) and separately 
by subscales. Alpha values range from 0.00 to 1.00. Higher values provide evidence for strong 
reliability.  
Scale/Subscale 
 
N of items  N α value  
Social Defeat Scale 
 
16 27 .89 
Entrapment Scale 
- Internal Entrapment  
- External Entrapment  
 
10 
6 
 
27 
27 
 
.84 
.90 
ISMI  
- Alienation Subscale  
- Stereotype Endorsement  
- Discrimination Experience  
- Social Withdrawal  
- Stigma Resistance  
 
6 
7 
5 
6 
5 
 
26 
26 
26 
26 
26 
 
.82 
.74 
.74 
.72 
.70 
 
GHSQ  
- Emotional Problems (-Q10) 
- Suicidal thoughts (-Q10) 
 
9 
9 
 
 
26 
24 
 
 
.77  
.82 
 
Problem scale – GlasMPT (overall) 
- Thinking problems category 
- Feeling problems category 
- Behavioural problems category 
23 
7 
9 
7 
25 
25 
25 
25 
.68 
.53 
.55 
.53 
Treatment Scale – GlasMPT  
Treatment options selected for: 
- Thinking Problems  
- Feeling Problems 
- Behavioural Problems 
 
 
21 
21 
21 
 
 
24 
23 
22 
 
 
.75  
.61 
.77 
Medical treatment (GlasMPT) selected for: 
- Thinking problems  
- Feelings problems  
- Behavioural problems  
 
4 
4 
4 
 
24 
23 
22 
 
.69 
.56 
.52 
Social support (GlasMPT) selected for: 
- Thinking problems  
- Feeling problems  
- Behavioural problems  
 
2 
2 
2 
 
24 
24 
22 
 
.40 
-.14 
.40 
Psychological treatment (GlasMPT) selected for: 
- Thinking problems  
- Feeling problems  
- Behavioural problems  
 
3 
3 
3 
 
24 
24 
22 
 
.55 
.39 
.42 
Alternative treatment (GlasMPT) selected for: 
- Thinking problems  
- Feeling problems  
- Behavioural problems  
 
12 
12 
12 
 
24 
24 
22 
 
.62 
.60 
.75 
Note. N= Sample size used in the analysis. Note that differences in sample sizes, reflect exclusion of 
scores for those participants who either did not respond to a certain question or item of a scale, or 
did not complete the whole questionnaire. These participants were excluded from the analysis. 
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Appendix 2.14:  Major Research Project Proposal  
 
An exploration of barriers to help-seeking among migrants experiencing psychosis 
           
          
Abstract 
Background: Research suggests that migrants are at greater risk of developing psychosis than 
non-migrants. One hypothesis is that pathways to care are more prolonged for migrants. Post-
migratory factors such as internalised stigma, experiences of social defeat and preference for 
non-medical treatment could contribute to delays in help seeking, by worsening mental health 
problems due to longer duration of untreated illness.  
Aims: This study will explore the role of internalised stigma, social defeat and  treatment 
preferences in help-seeking among migrants and non-migrants experiencing psychosis who 
are presenting to early intervention, acute, rehabilitation, and trauma services in Glasgow. 
Treatment preferences will be explored using a newly developed questionnaire.  
Methods: A cross-sectional design will be employed to compare differences between 
migrants and non-migrants. Psychometric properties of the newly developed measure will be 
also investigated.  
Applications: This study will help improve our understanding of barriers to help-seeking and 
will inform prevention and intervention strategies for psychosis. We also hope to establish a 
reliable measure of treatment preferences for use with individuals experiencing psychosis.  
 
 
 
 
109 
 
Introduction 
A growing body of research (Bhugra & Jones, 2001; Cantor-Graae, Zolkowska, & 
McNeil, 2005) indicates higher prevalence of non-affective and affective psychoses in first 
and second-generation immigrants compared with indigenous populations. These studies 
suggest a link between foreign migration and higher risk for the development of psychotic 
disorders, although the procedures underlying this relationship remain ambiguous. 
 Several hypotheses have been employed to explain this relationship, including the 
selective migration of predisposed individuals or the tendency of clinicians to misdiagnose 
schizophrenia in individuals of certain ethnicity (Ödegaard, 1932; Sashidharan, 1993).  Other 
studies have proposed that pre- or peri-migratory exposure to trauma could instead account 
for the high incidence of psychoses in refugees (Kinzie & Boehnlein, 1989; Leao et al., 
2006). 
It also appears that the pathways into care are different for migrant groups, with 
several studies indicating that certain ethnic groups have more adverse and complex 
pathways (contact with police or accident and emergency services before admission) to care 
than native residents (Bhui et al., 2003; Morgan et al., 2005a) or may experience significantly 
longer delays for accessing treatment (Boonstra, Sterk, Wunderink et al., 2012).  
Longer duration of untreated psychosis has been associated with poorer prognosis and 
treatment outcomes (Birchwood, Todd, & Jackson, 1998). While some delays occur because 
of failure of services in detecting psychotic prodromes (Etheridge, Yarrow & Peet, 2004), 
there is also a delay in seeking treatment in those who are already in contact with services 
when they develop psychotic symptoms (Norman, Malla, Verdi, Hassall & Fazekas 2004).  
It is possible that a range of risk factors are potentiated within the period between 
migration and the onset of recognised psychotic symptoms requiring care, which increases 
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the risk for developing psychosis (Cantor-Graae, Pedersen, McNeil, 2003). Factors such as 
stigma, experiences of social defeat (stress produced after prolonged exposure to social 
adversity) post-migration and a preference for non-medical treatments can contribute to 
delays in help seeking (Cantor-Graae & Selten, 2005; Thomson, Chaze, George & Guruge, 
2015). Therefore, understanding better the factors which impede treatment seeking among 
migrants is essential to improve prevention and early intervention strategies for psychosis. 
Aims & Hypotheses  
This study will explore internalised stigma (e.g. when a person considers stereotypes 
about mental illness to be self-relevant), experiences of social defeat, and treatment 
preferences among migrants and non-migrants being seen in out-patient clinics and treatment 
wards. The study will also evaluate the psychometric properties (reliability and validity) of a 
new measure of treatment preferences; the Glasgow Treatment Preferences Scale (GTPS). 
This measure was developed as, to date, there are no known measures assessing treatment 
preferences in British migrants. The following questions are posed:  
1) What are the treatment preferences of migrants and non-migrants experiencing 
psychosis? 
2) Is GTPS a valid and reliable measure of treatment preferences? 
3) Are there any differences between migrants and non-migrants in terms of 
internalised stigma, social defeat experiences and treatment preferences? 
 
We hypothesize that a) the GTPS will be a valid and reliable measure of treatment 
preferences for individuals experiencing psychosis and b) migrants will report experiencing 
greater internalised stigma, social defeat and greater preference for accessing non-medical 
therapies than non-migrants. 
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Plan of Investigation 
Participants 
The sample will consist of individuals with lived experience of psychosis who are 
currently presenting to early intervention services (i.e. ESTEEM), acute and long-term 
rehabilitation services across Glasgow. Participants presenting with psychotic symptoms 
(migrants and non-migrants) will be also recruited from the NHS GG&C trauma service (i.e. 
‘the Anchor’) as trauma has been associated with the emergence of psychosis in adult life 
(Bendall, Jackson, Hulbert, & McGorry, 2008).  
Inclusion and Exclusion Criteria 
Individuals will be eligible if they are currently in receipt of care from the above 
services. Experience of psychosis will be defined as presentation to clinical services with 
psychotic symptoms of sufficient severity and/or distress to require treatment. This will 
involve participants with a diagnosis of schizophrenia, schizoaffective, schizotypal or 
delusional disorder as defined by the ICD-10 (International Classification of Diseases of the 
World Health Organization, Tenth Edition), (World Health Organization; WHO, 1992), as 
well as participants who have not yet received a diagnosis but whose symptoms are of 
clinical concern. 
  Additional inclusion criteria include participants living in the Glasgow area and being 
over the age of 18 years old. Participants will be excluded if they are not eligible for consent 
(e.g. if substance misuse, head injury or an organic disorder is considered to be the primary 
cause of psychotic symptoms, if they have a learning disability, or if they experiencing an 
acute psychotic episode).  
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Measures 
Experience of Psychosis: A file diagnosis of a schizophrenia spectrum disorder by 
ICD-10 criteria (WHO, 1992), will be completed to confirm experience of psychosis and/or 
presentation of psychotic symptoms. Treatment Preferences: a draft questionnaire exploring 
treatment preferences has been developed under supervision of the academic supervisor of 
this project. This measure asks participants to rate their experience of certain types of 
treatment on a 10-point Likert scale (with 1=no experience at all and 10=a great deal of 
experience), across a range of domains (e.g. medical, psychological or social).  Participants 
are then asked to indicate their views on how beneficial each of the treatments presented may 
be for them (see Appendix A). The questionnaire will be reviewed by experts in the field and 
following receipt of their feedback, it will be refined and tested in the clinical setting.   
Internalised Stigma will be measured with The Internalised Stigma of Mental Illness 
Scale (ISMI; Ritsher, Otilingam, & Grajales, 2003), a 29-item scale that assesses service 
users' experiences of self-stigma.  The measure has strong internal consistency (α = 0.90) and 
test–retest reliability(r = 0.92) (Ritsher and Phelan, 2004). The Perceived Devaluation and 
Discrimination Scale (PDD) will be also used to measure felt stigma, which is the 
individual’s estimation of how the society may view a mental health service user (Link, 
1987). This scale also has excellent psychometric properties (Link, Mirotznik & Cullen, 
1991). 
Experiences of social defeat will be measured using two brief self-report 
questionnaires, the Social Entrapment and Defeat Scales (Gilbert & Allan, 1998). Both scales 
are administered together as they assess the same construct and have demonstrated good 
psychometric properties (Taylor, Wood, Gooding, Johnson, & Tarrier, 2009). The Social 
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Comparison Scale will be also used to assess participants’ view of themselves in relation to 
others (Allan & Gilbert, 1995).  
Design  
This study will employ a correlational (i.e. exploring associations between variables), 
cross-sectional (i.e. one time point of assessment), between groups design, as we aim to a) 
determine the psychometric properties of the GTPS, and b) to explore differences between 
migrants and non-migrants.  
Research & Recruitment Procedures  
This study will consist of two phases: 
Phase 1. An expert panel, which will consist of clinicians working with individuals 
with experiences of psychosis, will be asked to provide their views on the GTPS. Following 
receipt of the feedback, the measure will be refined before its psychometric properties are 
tested in the clinical setting.  
Phase 2. Staff at each service will identify eligible participants and will alert them to 
the study. Service users who express an interest in finding out more will be introduced to the 
researcher who will provide information about the study and obtain written consent. 
Participants will then attend for one data collection session and complete the GTPS, plus 
measures of social defeat and internalised stigma. It is estimated that the questionnaires will 
take approximately 30-45 minutes to complete. 
Data Analysis  
All data – including sociodemographic data such as gender, age etc. - will be collected 
and stored using a Statistical Package for Social Sciences (SPSS) dataset. Data will be then 
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analysed using descriptive and inferential statistics generated by IBM SPSS version 25.0 and 
will be summarised in written, graphic or tabular format.  
During phase 1, psychometric properties (e.g. internal consistency, face and/or 
content validity etc.) of the GTPS will be investigated. If the sample size is sufficient, 
exploratory factor analysis will be used to explore the factor validity of the questionnaire.  
In phase 2 of the study, independent-samples t-tests for  continuous  data  and  Chi-
squared  tests  for  categorical  data will be used  to  examine differences  between  groups 
(e.g. treatment preference in migrants vs. nom-migrants). Mann Whitney U tests will be used 
for data that are not normally distributed. If our hypotheses are supported, analysis will 
highlight significant differences between the two groups.   
Justification of sample size 
  As this is a pilot study, power and sample size calculations are tentative. There are 
several rules of thumb for feasibility studies attempting to estimate a parameter for use in a 
sample size calculation, such as Julious’s (2005) recommendation of a minimum of 12 
participants per group, or Browne’s (1995) suggestion of a total sample size of 30 or greater.  
G*Power (v.3.1.5. Faul, Erdfelder, Lang, & Buchner, 2007) was used to estimate the 
effect size for our study, if we recruited 12 participants per group. For a power of ≥0.8, α err 
prob = 0.05 and 12 participants per group, an effect size of 1.0 was calculated. Therefore, 
recruiting a sample of 12 participants per group, will be sufficient for our study as it will 
yield a large effect size. 
Settings and Equipment 
The study will take place across outpatient and inpatient settings in the area of 
Glasgow. Early intervention services for psychosis (i.e. ESTEEM), acute, rehabilitation and 
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trauma services (i.e. ‘the Anchor’) will be approached to recruit participants. Self-report 
measures, consent forms, information and debriefing sheets will be used during the 
recruitment period. An encrypted laptop or computer with access to SPSS will be used to 
analyse data. 
Health and Safety Issues 
Participant safety issues: 
As part of the informed consent process, participants will be advised of how to access 
support should they experience distress following their participation to the study. This will 
include a statement of the researcher’s obligation to inform appropriate agencies if they 
believe the individual, or a third party, to be at risk of harm.  
Researcher safety issues: 
 Research interviews will be conducted within staffed NHS sites during normal 
working hours (between 9 and 5pm). The researcher will become familiar with local health & 
safety protocols and have an awareness of how to access support if needed.  
Ethical Issues  
The study will be conducted only after ensuring favourable ethical approval by the 
West of Scotland Research and Ethics Committees. Management approval will be also sought 
from the NHS Greater Glasgow and Clyde Research and Development Office. 
Participants will be recruited only after providing their informed written consent. 
Participants who lack capacity to consent will not be included in the study. Prior to 
participating, named clinicians will be contacted to confirm each participant’s capacity for 
consent. Thereafter, individuals will be asked to read an information sheet about the project 
and then complete a consent form.  
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During data collection, completed questionnaires will be stored in a locked drawer on 
each site. Data will be then coded and entered in a password encrypted SPSS file, in line with 
the, University of Glasgow and NHS GG&C data protection, confidentiality and research 
ethics guidelines and in line with the Data Protection Act 1998. All cases will be anonymised 
to ensure confidentiality and will be assigned a unique case number.  Data will be stored on 
an encrypted computer throughout the data collection and analysis period. Only the 
researcher will have access to data stored in the computer and following the analysis the data 
will be destroyed. Finally, the right of withdrawal will be explained fully to service users 
before taking part in the study. 
Financial Issues 
Stationary costs for copies of self-report measures, consent forms and information and 
debriefing sheets will be incurred. Use of NHS GG&C translation services will be also 
required for those participants who can’t read or speak English. Finally, travel expenses may 
be reimbursed to assist participants from outpatient settings attending the data collection 
session (see Appendix B). 
Timetable 
Time Major Task/s 
September 2017 Submission of the MRP outline to the Academic Supervisor. 
Begin Literature Review. 
December 2017 Submission of the draft proposal to the Academic Supervisor 
February 2018 Submission of the MRP Proposal to the Academic Supervisor 
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May 2018 Submission of the Final Approved MRP Proposal & 
Submission of ethics forms to the NHS REC (Research & 
Ethics Committee) 
May- August 2018 Obtain ethics approval from West of Scotland REC and begin 
writing background and literature chapters. 
August 2018 – March 
2019 
Data collection and analysis. Begin writing analysis and 
discussion chapter. 
March 2019  Submit first draft of thesis 
July 2019 Revise first draft and submit final MRP project 
 
Practical Applications 
The proposed study will make a significant contribution to the current understanding 
of barriers to help-seeking in migrants experiencing psychosis and it will help inform 
interventions and improve prevention strategies for psychosis. We also hope to establish a 
reliable measure of treatment preferences for use with individuals experiencing psychosis. 
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